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7Abstract
Panic disorder (PD) is severe anxiety disorder that follows a chronic course if left untreated. 
The recurrent panic attacks and persistent worrying of new attacks that are characteristic of 
PD is highly distressing and can lead to extensive disability. PD is also associated with a 
malign clinical course, and the physiological changes characteristic of PD, such as altered 
cardiac regulation is associated with increased risk of somatic illness. 
We compared physical exercise (PE) in groups to group cognitive behaviour therapy (CBT) as 
treatment for PD in a randomised clinical trial (RCT). Thirty six patients with PD with or 
without agoraphobia were recruited for participation in either PE three times per week or CBT 
once a week for twelve weeks. Participants were assessed twice prior to treatment initiation. 
They were thereafter assessed immediate post treatment, and at six and twelve months 
following treatment termination. We found CBT to yield significantly better long-term effects 
on the primary outcome measures, though PE still yielded large effects on key measures of 
panic symptoms and severity, also one year following treatment termination. Importantly, 
rates for clinically significant change were significantly higher for CBT, and further indicated 
that the majority of subjects in the PE group had not fully recovered from their disorder. 
We also investigated the relationship between vagally mediated heart rate variability (HRV) 
and cognitive executive functioning in the same sample of patients, and found that these 
measures were consistently associated. This extends previous research and provides support 
for the hypothesised relationship between altered functioning in the prefrontal cortex (PFC) 
and vagally mediated HRV. We also explored the relationships between these measures and 
clinical variables, and found both cognitive inhibition and HRV to be related to both severity 
8and duration of the panic disorder. This suggests that cardiac health is related to both 
cognitive functioning and the clinical state and duration of PD. 
 Finally, we assessed the same participants on a measure of subjectively reported sleep 
impairment. We investigated the relationships between this measure and both vagally 
mediated HRV and scores on cognitive inhibition, and found both sleep onset latency (SOL) 
and disturbances during sleep to be related to these physiological and cognitive measures. 
Furthermore, these relationships were independent of level of depression, and the results 
provide support for the psychobiological inhibition model of insomnia and extend previous 
findings in support of this model. 
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1.0 Introduction 
This thesis is an investigation into the treatment of panic disorder. It also aims to elucidate the 
psychophysiological concomitants of this anxiety disorder, and how these concomitants can 
be related to the development of the disorder itself and co-morbid disorders, such as sleep 
disturbance. In the following subsections of this introduction, the background for the current 
research aims will be presented. Thereafter these aims are delineated, with hypotheses and 
research questions presented for each study, followed by a description of the methods 
employed to investigate these. A results-section will summarise the main findings for each 
study, before these findings and their implications and limitations will be discussed.
The thesis is a synthesis of the three papers upon which it is based, and readers are referred to 
the reproductions of these papers that are attached for reference and additional details, figures 
and tables. 
1.1 Panic Disorder 
Panic disorder (PD) is a severe and prevalent anxiety disorder characterised by spontaneous 
and recurrent panic attacks. These attacks are experienced as highly distressing, and they are 
frequently accompanied by beliefs and fears of dying, going mad, fainting, or acting 
uncontrollably. The physiological symptoms experienced during the attacks are pronounced, 
and include palpitations, difficulty breathing, feeling suffocated, numbness, tingling 
sensations, chest pain, sweating, feeling hot and/or cold and a feeling of separation from 
reality. The marked bodily symptoms are often interpreted as indications of somatic illness, 
such as a heart attack or suffocation, and many patients seek help at emergency units or are 
referred for cardiac evaluation during the initial attacks (American Psychiatric Association 
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[APA], 2000; Dammen, Arnesen, Ekeberg, Husebye, & Friis, 1999; Jonsbu et al., 2009). 
Furthermore, PD frequently co-occurs with agoraphobia, where patients develop a fear of 
places and situations in which they feel trapped or cannot easily escape if a panic attack 
should occur, or where they expect an attack to occur. This co-morbidity can severely disrupt 
activities of daily life and social functioning (APA, 2000).  Estimates of lifetime prevalence 
rates for PD in the general population range from 3.5-4.7% (Bijl, Ravelli, & van Zessen, 
1998; Kessler et al., 2005; Kessler et al., 1994), whereas PD with agoraphobia is reported to 
have a lifetime prevalence of 1.1-1.5% (Kessler et al., 2006; Kessler et al., 1994). However, 
prevalence rates for PD are suggested to be substantially higher within clinical populations, 
such as individuals referred for mental health consultations and heart disease polyclinics, 
where PD has been estimated to be present in as many as 10% and 60% of patients, 
respectively (APA, 2000). PD is not only a severe and distressing disorder in itself. It is also 
the most frequent co-morbid disorder with depression (Roy-Byrne et al., 2000), a combination 
associated with poorer treatment outcome, more severe functional impairment, more suicide 
attempts, and greater severity (Roy-Byrne et al., 2000). Even the presence of panic attacks is a 
risk factor for the development of mental disorders of any kind, and is also associated with 
greater impairment and help-seeking (Goodwin et al., 2004; Kessler et al., 2006). PD is 
further characterised by reduced heart rate variability (HRV; Cohen et al., 2000; Klein, 
Cnaani, Harel, Braun, & Ben-Haim, 1995; Middleton, Ashby, & Robbins, 1994; Yeragani et 
al., 1990; Yeragani et al., 1993). This is significant, as decreased HRV has been linked to 
increased risk of all-cause mortality (Jouven, Zureik, Desnos, Guérot, & Ducimetière, 2001; 
Thayer, Yamamoto, & Brosschot, 2010). Decreased HRV has also been demonstrated to be an 
independent and strong predictor of mortality following myocardial infarction (Malik et al., 
1996). PD is associated with an increased risk of developing coronary heart disease (CHD; 
Gomez-Caminero, Blumentals, Russo, Brown, & Castilla-Puentes, 2005), and reduced HRV 
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in these patients has indeed been linked to this increased mortality risk (Alvarenga, Richards, 
Lambert, & Esler, 2006; Garakani et al., 2009; Habib, 1999; Weissman, Markowitz, 
Ouellette, Greenwald, & Kahn, 1990). Such somatic consequences related to PD underline the 
importance of providing treatment to those who suffer from this disorder. 
1.2 Treatment of Panic Disorder 
Numerous studies have investigated different treatment options for PD, and both 
psychopharmacological and psychotherapeutic treatment options have been developed. 
Psychotherapy appears to be most effective (Andrews, Creamer, Crino, Hunt, & Lampe, 
2003), and this is also the recommended treatment option (McHugh et al., 2007; McManus, 
Grey, & Shafran, 2008; National Institute for Health and Clinical Excellence [NICE], 2011). 
Broadly speaking, it could be said that effective psychotherapeutic treatment models for PD 
has existed for the last 25 years. Two main models for panic treatment seem to be prevailing. 
These consist either of Cognitive Therapy for PD according to the model developed by David 
Clark and colleagues (Clark, 1986; Clark et al., 1994) or the Panic Control Treatment for PD 
developed by Barlow and colleagues (Barlow, 2002). Both of these treatments are referred to 
as cognitive behaviour therapy (CBT), and are considered to yield similar treatment responses 
(Clark et al., 1999; McManus et al., 2008), with remission rates around 80% for patients with 
PD (Andrews et al., 2003; McManus et al., 2008).
In terms of psychopharmacological approaches, selective serotonin reuptake inhibitors 
(SSRIs) are the preferred option (NICE, 2011; Pull & Damsa, 2008), providing treatment 
responses of approximately 60%, depending on the criteria used to determine remission (Pull 
& Damsa, 2008). Tricyclic antidepressants (TCAs) were the previously preferred 
psychopharmacological treatment for PD, citing equivalent treatment responses (Pull & 
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Damsa, 2008). TCAs are however less well tolerated by patients than SSRIs. A caveat 
concerning pharmacotherapy for PD is the high rates of relapse, regardless of compliance, 
following such treatment (Simon et al., 2002).
Unfortunately, while manuals for CBT for PD are readily available, it has been 
documented that as with many other evidence based treatments, CBT for PD is rarely offered 
to those who suffer from it (Shafran et al., 2009). Psychopharmacological treatment is more 
readily provided, as this can be administered by the patients’ general practitioner. However, 
with reference to the high relapse rates associated with this treatment, a substantial proportion 
of patients seeking help for PD would not be cured of their disorder. In addition, 
psychopharmacological treatment is not acceptable to all patients; neither is CBT nor other 
forms of psychotherapy. A recent and promising development is the emergence of 
computerised CBT (CCBT). This paradigm has shown high remission rates (Carlbring et al., 
2006), though somewhat lower than what has been found for ordinary face-to-face CBT 
(Haug, Nordgreen, Öst, & Havik, 2012). Increased availability of this treatment option will 
hopefully provide CBT more readily to patients suffering from PD.
Based on aforementioned state of affairs, the need to develop additional treatment 
options for PD seems clearly warranted. Currently, only a relatively small portion of patients 
receive the recommended treatment for PD (i.e. CBT), and the need to develop a broader 
range of treatment options is ever important, as not all patients tolerate or benefit from neither 
CBT nor psychopharmacological treatment. 
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1.3 Physical Exercise for Panic Disorder 
1.3.1 Empirical background 
Physical exercise (PE) has long been investigated for the reduction of anxiety. Several cross-
sectional studies have shown that physical active people have decreased prevalence of anxiety 
disorders (Goodwin, 2003; Muhsen, Lipsitz, Garty-Sandalon, Gross, & Green, 2008; Ströhle 
et al., 2007; ten Have, de Graaf, & Monshouwer, 2011), or that they report lower levels of 
anxiety compared to inactive people (De Moor, Beem, Stubbe, Boomsma, & De Geus, 2006; 
Harvey, Hotopf, Overland, & Mykletun, 2010). A substantial number of studies have also 
shown that PE can reduce anxiety levels. However, most of these studies have included 
healthy volunteers (Long & van Stavel, 1995; Wipfli, Rethorst, & Landers, 2008). It has also 
been demonstrated that PE can reduce anxiety in subjects with elevated anxiety levels 
(Petruzzello, Landers, Hatfield, Kubitz, & Salazar, 1991). Fewer studies have investigated the 
clinically efficacy of PE in reducing anxiety in patients that primarily suffer from an anxiety 
disorder. Sexton, Mære, and Dahl (1989) found PE to reduce anxiety in a mixed sample of 
anxious and depressed patients. A more recent study found PE to have a moderate to small 
treatment effect on generalised anxiety disorder (Herring, Jacob, Suveg, Dishman, & 
O’Connor, 2012). The perhaps first investigation into the effect of PE on PD was published in 
1974 by Orwin. This was a case report, in which situational phobia was treated with the help 
of physical exertion. Viewed in hindsight, it is not unlikely that the patient in this case report 
today would have been diagnosed with agoraphobia and PD. Up till recently, only three 
studies had evaluated the use of PE as treatment for PD. In 1989, Martinsen, Sandvik and 
Kolbjørnsrud published a study on a mixed sample of inpatients that took part in PE one hour 
a day for eight weeks in addition to psychodynamic group-treatment three times per week. 
This treatment led to a significant reduction of symptoms in patients with PD, but symptom 
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reduction was not found to be significant when the patients were reassessed twelve months 
later. In 1998, Broocks et al. published results from a randomised clinical trial (RCT) in 
which patients with PD either received the TCA clomipramine, pill placebo or performed PE. 
Treatments ran for ten weeks, and participants in the PE-group were requested to complete a 
4-mile route at least three times per week, with intensity progressing from walking to running. 
In addition, participants ran together under supervision once a week. Those authors found PE 
to be significantly better than placebo, and not significantly different from clomipramine on 
some primary outcome measures, though they concluded that clomipramine appeared to yield 
a more rapid effect. In this otherwise well-designed study the authors did not report any long-
term effects, nor was the clinical significance of the results assessed. A similar exercise 
regime was employed in a more recent study by Wedekind et al. (2010). This study compared 
the SSRI paroxetine with pill placebo, either in combination with PE or relaxation. When PE, 
together with either placebo or paroxetine was compared against relaxation and either of these 
additional treatments, no significant differences were found. However, this design, in which 
both PE and relaxation was administered in combination with pharmacological treatment, 
challenges the validity and generalisability of these findings on the efficacy of PE for PD. 
Also, PE plus placebo was found to improve ratings of symptom severity as effectively as 
paroxetine plus relaxation, and PE plus paroxetine was overall found to yield the largest 
effects.
It has also been demonstrated that PE can have acute anti-panic effects, reducing the 
risk of panic attacks in both healthy volunteers (Esquivel, Schruers, Kuipers, & Griez, 2002; 
Smits, Meuret, Zvolensky, Rosenfield, & Seidel, 2009; Ströhle et al., 2005) and in patients 
with PD (Esquivel et al., 2008; Ströhle et al., 2009) following a single bout of PE. 
Furthermore, three RCTs have found that PE reduces anxiety sensitivity (Broman-Fulks, 
Berman, Rabian, & Webster, 2004; Broman-Fulks & Storey, 2008; Smits, Berry, Tart, & 
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Powers, 2008) in subjects with increased levels of sensitivity to anxiety and symptoms of 
anxiety after just 6 sessions of PE performed over 2 weeks time. Anxiety sensitivity seems to 
precipitate spontaneous panic attacks and is a vulnerability factor for the development of PD 
(Schmidt, Lerew, & Jackson, 1999). 
 Thus there appears to be some accumulated evidence to suggest that PE can be a 
relevant intervention for anxiety, and even more so for PD. What is lacking from the 
empirical base listed above is a replication and extension of the study by Broocks et al. 
(1998), where PE can be compared against an evidence-based treatment for PD in which also 
its long-term effect and the clinical significance of any changes are assessed. The need for PE 
to be compared against an established psychotherapeutic approach such as CBT has been 
called for (Broman-Fulks & Storey, 2008), and there has also been a general 
acknowledgement of the need for more clinically relevant studies in the field of PE as 
treatment for mental disorders (Lawlor & Hopker, 2001; Salmon, 2001). 
1.3.2 Theoretical background for investigating physical exercise 
for panic disorder 
A wide range of different mechanisms have been proposed to explain the effects of PE on 
mental health and well-being, and a thorough presentation and discussion of these can be 
found in Buckworth and Dishman (2002) and in Petruzzello et al. (1991). It is however clear 
that we are far away from a conclusive model that explains the anxiolytic effect of PE 
(Ströhle, 2009), and the lack of consensus regarding these mechanisms constitute a major 
obstacle in the utilisation of PE in the treatment of mental illnesses (Scully, Kremer, Meade, 
Graham, & Dudgeon, 1998). Mechanisms that are related to the concomitants investigated in 
the current thesis will be presented below, together with mechanisms suggested to be 
specifically related to PE for PD. 
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Exposure to bodily sensations (i.e. interoceptive exposure) is one of the mechanisms that has 
been suggested to explain the efficacy of PE for PD (Smits et al., 2008). This means that 
patients with PD learn that the physical sensations associated with both anxiety and PE are 
benign. However, as cited above, an acute bout of PE has also been shown to decrease the risk 
of panic attacks following challenges such as inhalation of CO2 or injection of 
cholecystokinin tetrapeptide (CCK-4) in healthy subjects (Esquivel et al., 2002; Smits et al., 
2009; Ströhle et al., 2009) and in patients with PD (Esquivel et al., 2008; Ströhle et al., 2009). 
One interesting and promising explanation for this acute effect is related to the findings of 
increased plasma concentrations of atrial natriuretic peptide (ANP) following exercise. It has 
been shown that an ANP injection reduces anxiety and risk of panic attacks in patients with 
PD, and furthermore that the anxiolytic effect of exercise correlated with exercise-induced 
increase in ANP concentrations (Ströhle, Feller, Strasburger, Heinz, & Dimeo, 2006; Ströhle, 
Kellner, Holsboer, & Wiedemann, 2001). Still, the increase in ANP following exercise has 
been shown to be highest in untrained subjects (Rogers, Tyce, Bailey, & Bove, 1991), thus the 
effects of prolonged exercise must be explained by additional mechanisms. Apart from 
exposure to bodily sensations, several neurotransmitters related to regulation of anxiety have 
also been found to be sensitive to PE (please consult O'Connor, Raglin, and Martinsen (2000) 
for a detailed account). Particularly relevant here are the findings that PE leads to increased 
levels of Gamma-Aminobutyric Acid (GABA) in subcortical brain areas (i.e. corpus striatum; 
Dishman et al., 1996). This is emphasised here as GABA activity has been related to the 
regulation of heart rate (HR) and HRV (Friedman, 2007; Thayer, Hansen, Saus-Rose, & 
Johnsen, 2009), and this will be described more closely in the following section. GABA 
neurons represent the most widely available inhibitory neurons in the cerebral cortex (Thayer 
& Lane, 2000), and deficient functioning of the GABAA receptor in the hippocampus and 
frontal cortex have been associated with anxiety (Crestani et al., 1999). Although these 
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findings are based on animal models, the key point here is that the study by Dishman et al. 
(1996) indicates that the GABAergic system is sensitive to PE.
Another model that is relevant for the concomitants investigated in the current thesis is 
Solomon’s opponent-process model for motivation (Solomon, 1980). This has been suggested 
as a model for the anxiolytic effects of PE (Petruzzello et al., 1991), and the model posits that 
the organism (i.e. brain) seeks to maintain homeostasis by counteracting the effects of 
different external stimuli by an opponent reaction. In the case of PE, the exercise represents 
an anxiety-provoking stimulus that is counteracted by relaxation. Endorphin release has been 
suggested as the mechanism behind this descriptive model. However, while some studies have 
supported this model (Boutcher & Landers, 1988; Petruzzello, Jones, & Tate, 1997), 
endorphins have largely been disregarded as the mechanism behind mood changes following 
PE (Buckworth & Dishman, 2002). Other mechanisms have therefore also been related to this 
model. One proposition has been a change in the balance between the sympathetic nervous 
system (SNS) and the parasympathetic nervous system (PNS), with PE leading to a relative 
increase in the influence of the PNS over the SNS resulting in net relaxation (Petruzzello et 
al., 1991). Although the empirical support for this hypothesis has been scant, the emphasis put 
on a change in balance between the PNS and the SNS is relevant to the theoretical framework 
underlying the current thesis where HRV is investigated. 
Measurement of HRV is a non-invasive method for assessing the influence of the PNS 
relative to the SNS (Malik et al., 1996), and in line with the above, HRV has been 
demonstrated to be sensitive to PE. Research on cardiac patients (Coats et al., 1992), young 
adults with hypertension (Somers, Conway, Johnston, & Sleight, 1991), and healthy adults 
(Levy et al., 1998) have found HRV to increase following PE. A more recent study found that 
only four weeks of detraining resulted in a decrease in HRV (Hansen, Johnsen, Sollers, 
Stenvik, & Thayer, 2004). Furthermore, the previously mentioned fact that HRV is reduced in 
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patients with PD not only underlines the relevance of this measure with regard to PD and PE, 
but also strengthens the theoretical rational for expecting PE to be a viable treatment option 
for PD. This line of thought could be extended to a more recently suggested model for 
explaining the beneficial effects of PE on mental health. Salmon (2001) argue that this effect 
can be ascribed to the increased adaptability resulting from PE, an argument that has also 
been advocated in more recent literature (Ströhle, 2009). HRV has repeatedly been suggested 
as an index of the individual’s flexibility and adaptability (Appelhans & Luecken, 2006; 
Kashdan & Rottenberg, 2010), and the documented changes in HRV following PE would thus 
be compatible with this understanding. 
1.4 Panic Disorder, HRV and Executive Functioning 
The panic attacks experienced by patients with PD have dramatic presentations of autonomic 
activation. Symptoms such as tachycardia and palpitations have led to the investigation of 
possible cardiac dysregulation related to PD. In addition to being a risk factor in its own right, 
decreased HRV has been investigated within a theoretical framework that is relevant for the 
understanding of developmental and clinical concomitants of PD. 
HRV describes the variations in beat-to-beat changes in HR, which is determined by 
the combined activity of the sympathetic and the parasympathetic nervous system. The 
innervations of these systems at the sinoatrial node of the heart regulate HR in an antagonistic 
relationship: A relative increase in sympathetic activity accelerates HR, whereas a relative 
increase in parasympathetic activity decelerates it. The sympathetic nervous system mediates 
slower and prolonged increases in HR, while the parasympathetic nervous system exercises 
the immediate changes in heart rate directly through the vagus nerve (Friedman, 2007). 
Reduced vagal control of the heart’s beats is associated with a reduction in HRV, and the 
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parasympathetic inhibitory control of the heart through the vagus nerve dominates cardiac 
control (Levy, 2006). The high frequency (HF) component (i.e. the most rapid changes) of 
HRV is considered to be an index of the vagal control of the heart (Malik et al., 1996). It has 
further been suggested that this vagal regulation is controlled by inhibitory neuronal activity 
in areas of the prefrontal cortex (PFC; Thayer, 2006), and that decreased inhibitory cortical 
activity is related both to the development of psychopathology as well as decreased HRV 
(Ahern et al., 2001; Barbas, Saha, Rempel-Clower, & Ghashghaei, 2003; Thayer & Lane, 
2007). A comprehensive account of the neurological pathways through which this regulation 
could take place is presented by Thayer et al. (2009). The key point argued by those authors is 
that decreased HRV results from decreased inhibitory control from prefrontal areas of the 
brain, mainly resulting from decreased GABA activity in these areas of the PFC. Importantly, 
the increase in HR and decrease in vagally mediated HRV seen in anxiety conditions such as 
PD, can be conceptualised rather as a condition of faulty brakes (i.e. inadequate inhibition) as 
opposed to a ‘sticky accelerator’ (i.e. hyperarousal; Friedman, 2007). 
The link between vagal cardiac control and activity in areas in the PFC, has been 
documented both in studies with human subjects (Lane et al., 2009; Ter Horst, 1999) and in 
animal models (Barbas et al., 2003; Ter Horst, 1999). These relationships have recently been 
supported in a meta-analysis in which significant associations between neuronal activity in the 
ventromedial PFC and HRV was found (Thayer, Åhs, Fredrikson, Sollers, & Wager, 2012). 
The PFC is a part of the brain that has been linked to the so called executive functions 
(Alvarez & Emory, 2006; Goldman-Rakic, 1998; Ridderinkhof, van den Wildenberg, 
Segalowitz, & Carter, 2004), including working memory, the ability to shift and sustain 
attention, exert cognitive inhibition, and exercise general mental flexibility (Alvarez & 
Emory, 2006). It would be expected that reduced activity in the PFC would affect the 
cognitive abilities related to this brain region (Barbas et al., 2003; Thayer et al., 2009), and 
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thus that vagally mediated HRV was associated with executive functions. Such a link has 
been demonstrated in several studies with healthy adults (Hansen et al., 2004; Hansen, 
Johnsen, & Thayer, 2003; Mathewson et al., 2010), children (Suess, Porges, & Plude, 1994), 
and infants (Richards & Casey, 1991). It should be noted that Duschek et al. (2009) failed to 
find support for such association, however the validity of this negative finding has been 
challenged (Elliot, Payen, Brisswalter, Cury, & Thayer, 2011). More importantly, the 
directionality of the findings have been consistent, with higher HRV being associated with 
better performance on measures of executive functioning and vice versa. This association has 
only to a limited extent been investigated in anxious subjects. Johnsen et al. (2003) assessed a 
small sample of dental phobics, and found that those with low HRV showed longer latencies 
in an emotional Stroop paradigm, compared to subjects with high HRV. However, in this 
study measurements of HRV were collapsed over all four assessments, including baseline, 
exposure, Stroop assessment, and recovery. As HRV is known to decrease during assessment 
of executive abilities (Boutcher & Boutcher, 2006; Delaney & Brodie, 2000; Mathewson et 
al., 2010), it is unclear to what extent these findings reflect a relationship between baseline 
HRV and executive functioning, and how much they were influenced by performance-related 
alterations during the Stroop assessment. Thus, the relationship between baseline vagally 
mediated HRV and executive functioning in anxious subjects is still in need of further inquiry.
1.5 Panic Disorder and Sleep 
As described initially, PD and panic attacks are associated with both a malign clinical course, 
as well as with increased risk of developing co-morbid disorders and conditions. Studies have 
shown that problems with sleep is common across psychiatric conditions (Okuji et al., 2002), 
with insomnia being the most commonly reported sleep disorder (Lichstein, Taylor, McCrae, 
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& Ruiter, 2011). Insomnia refers to complaints of ongoing difficulty falling asleep, staying 
asleep, waking up too early, or of nonrestorative sleep during the last month. The complaint 
must cause clinically significant distress or impairment in important areas of life, such as 
social and occupational. In addition to the sleep complaint, those affected by insomnia report 
impaired daytime function in spite of adequate opportunity to sleep (Harvey & Spielman, 
2011).
Though many models have been developed for explaining insomnia, this disorder has 
long been considered a disorder of hyperarousal (Perlis, Shaw, Cano, & Espie, 2011). 
Patients with PD have altered regulation of arousal, and it is therefore not surprising that the 
characteristics of sleep and prevalence of sleep impairment have been investigated in these 
patients. Sleep complaints is a diagnostic criteria for some anxiety disorders, such as 
posttraumatic stress disorder (PTSD) and generalised anxiety disorder (GAD), but not for PD. 
Nonetheless, studies have shown that approximately 70% of patients with PD report sleep 
impairments (Mellman & Uhde, 1989; Overbeek, van Diest, Schruers, Kruizinga, & Griez, 
2005; Stein, Chartier, & Walker, 1993).
 Stein et al. (1993) found patients with PD to report overall impaired sleep quality as 
measured by the global PSQI score when compared to healthy controls. Patients in that study 
scored higher (more poorly) than controls on four of the seven subscales of the PSQI: Sleep
quality, Sleep latency (i.e. SOL), Disturbed sleep, and Daytime dysfunction. As reported 
previously, PD also frequently co-occurs with depression. Depression is known to be closely 
associated with sleep disturbances. Still, it has been shown that sleep impairment is a frequent 
problem for patients with PD, also when patients with co-morbid depression are excluded 
(Overbeek et al., 2005). As such, it would seem that sleep impairment is an important part of 
the clinical picture in PD, as well as other anxiety disorders, and a shared underlying 
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mechanism between insomnia and anxiety has indeed recently been suggested (Uhde et al. 
2009).
1.5.1 Sleep and cognitive inhibition 
From what has been described above, both PD and insomnia are conditions that have been 
described by poorly regulated arousal. In the case of PD, and anxiety disorders in general, this 
increased arousal has more recently been conceptualised rather as a condition with impaired 
ability to ‘de-arouse’. Interestingly inhibition, or lack thereof, has increasingly been 
implicated as a mechanism for the development and perpetuation of sleep disturbances 
(Bastien, 2011; Perlis et al., 2011). Several models have been suggested for the development 
and perpetuation of insomnia. Two key models of insomnia (Perlis et al., 2011), the 
neurocognitive model of insomnia and the psychobiological inhibition model of insomnia, 
describes cortical arousal as central to the development and precipitation of insomnia 
(Borbély, 1982; Espie, 2002; Perlis, Giles, Mendelson, Bootzin, & Wyatt, 1997). One of the 
main differences between these models is that while the neurocognitive model posits a 
conditioned state of hyperarousal, the psychobiological inhibition model of insomnia 
emphasise the failure to inhibit wakefulness (e.g. arousal) as a key mechanism in the 
development and exacerbation of insomnia. A recent review of the evidence for these two 
models concluded that both models can account for difficulties in initiating and maintaining 
sleep (Bastien, 2011). Studies using event related potentials (ERPs) indicate that decreased 
cognitive inhibition is related to increased SOL (Bastien, St-Jean, Morin, Turcotte, & Carrier, 
2008). Furthermore, cognitive events such as rumination, worry and intrusive thoughts are 
frequently reported by patients suffering from insomnia (Perlis et al., 2011), and such 
distressing thoughts and perseverative processing are considered central for the development 
and exacerbation of insomnia (Harvey, 2002). According to Eysenck et al. (2007), anxiety and 
worry are related to the ability for exercising cognitive inhibition and attentional control. 
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Thus, it would seem reasonable to expect that aspects of sleep impairment could be related to 
executive functioning, and more precisely to cognitive inhibition, and that these could also be 
assessed with other methods than ERP, such as neuropsychological assessment.
However, regarding cognitive impairments related to insomnia, neuropsychological 
assessments of these have so far mainly yielded inconclusive findings (Shekleton, Rogers, & 
Rajaratnam, 2010). Shekleton et al. (2010) concluded that the apparent lack of conclusive 
findings can partly be attributed to heterogeneity in the samples used in the studies that have 
investigated this. Furthermore, Shekleton et al. (2010) suggest that potential overlap between 
the clinical group and the control group could have distorted or diluted possible group 
differences. In addition, they concluded that lack of findings is partly due to the use of 
measures that lack sufficient sensitivity to detect differences between insomniacs and 
controls. In this regard they pointed out that the most consistent findings concerned executive 
functions, and suggested that differences between insomniacs and controls are most likely to 
be found on sensitive measures of these functions.
How then could the role of neuropsychological characteristics in insomniacs be 
investigated while circumventing the challenges associated with possibly overlapping or 
heterogeneous samples? One way to address this could be to investigate sleep impairment in a 
sample with a high prevalence of sleep disturbances that could also be expected to provide 
variability on measures of neuropsychological functioning. Patients with PD would be a 
relevant sample in this regard, as a large proportion of these patients are known to suffer from 
insomnia. Furthermore, PD is associated with decreased HRV, a measure that has been 
positively associated with executive functioning. Studies have also indicated that patients with 
PD have impaired inhibitory control (Dupont, Mollard, & Cottraux, 2000) and executive 
functioning (Lautenbacher, Spernal, & Krieg, 2002), though results in this area have not been 
unequivocal (van den Heuvel et al., 2005). Thus, a sample of patients with PD could be 
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expected to provide variability on both measures of executive functioning and sleep 
impairment. Cognitive inhibition has been related to sleep impairment both theoretically and 
empirically, while also being a key executive function. To investigate the relationship 
between cognitive inhibition and sleep impairment in a sample of patients with PD would thus 
seem to be a viable approach, and it would also circumvent the challenges described by 
Shekleton et al. (2010) reiterated above. 
1.5.2 Sleep and HRV 
The line of reasoning presented above could also adhere to the investigation of a possible 
association between HRV and sleep impairment. If cognitive inhibition is related to, and 
important for sleep disturbances, then HRV could also be related to sleep disturbances. Indeed 
HRV has been found to be related to insomnia (Spiegelhalder et al., 2011), but in line with the 
concerns raised by (Shekleton et al., 2010), this was only found for insomniacs with 
objectively determined reductions in sleep. Yang et al. (2011) on the other hand found HRV 
to be reduced also in patients with insomnia without taking such measures, whereas Bonnet 
and Arand (1998) found HRV to be reduced in objectively determined insomniacs. Thus, it 
would seem viable also to investigate the relation between measures of sleep impairment and 
HRV in a sample of patients with PD, as also here variability on both of these measures 
would be expected.
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2.0 Background and Main Aims 
As presented previously, PD is not only a severe disorder with reference to the experienced 
distress and restriction of movement that is associated with the disorder. It has also high co-
morbidity with other disorders such as depression. Patients with PD have also been found to 
have an altered cardiac regulation, which has been linked to the increased risk of CHD and the 
increased mortality associated with this disorder. Regarding treatment, several options have 
been developed, although it appears that the most effective treatment, CBT, is not readily 
available to these patients. Development of acceptable treatment options is ever important, 
particularly for a severe disorder such as PD, where spontaneous recovery is known to be rare 
(Wittchen & Essau, 1993). PE has shown promising results for PD, and calls have been made 
for this treatment to be compared against a relevant treatment option, such as CBT, that has 
status as an evidence-based treatment for PD. Furthermore, in previous research on PE for 
PD, long-term effects as well as clinical significance of changes have not been sufficiently 
investigated.
 HRV has been shown to be a powerful non-invasive measure, and decreased levels of 
HRV have been associated with an increased risk of malign development in both mental and 
somatic disorders. It has been documented that HRV levels are linked to measures of 
executive functioning, but this has not been investigated in the group of patients that has 
consistently been linked to altered vagally mediated cardiac regulation; patients suffering 
from PD. 
 Sleep impairment is known to be prevalent in the patients with PD. These patients are 
also characterised by decreased vagally mediated HRV, which has been associated with both 
neuronal inhibition in the PFC and executive functioning. Anxiety has been linked to 
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impaired executive functioning (Eysenck et al., 2007), and in particular to cognitive 
inhibition. Studies also suggest that patients with PD have impaired inhibitory ability (Dupont 
et al., 2000). Failure to inhibit arousal is considered a key mechanism in the psychobiological 
inhibition model, and cognitive inhibition, as measured by ERPs has been linked to increased 
SOL. Attentional shifting has also been implicated in sleep impairment (Benitez & Gunstad, 
2012), thus two key executive functions have been linked to sleep impairment and symptoms 
of insomnia. Research on cognitive impairments associated with insomnia has proven elusive, 
and Shekleton et al. (2010) attributed the lack of conclusive findings in this area to possible 
clinical overlap between insomniacs and control group. Those authors also emphasised the 
importance of using measures sufficiently sensitive to impairments in these patients, and 
further suggested that such impairments would most likely be found on measures of executive 
abilities. By assessing the relationships between symptoms of sleep impairment and 
physiological and cognitive measures in a sample of patients with PD, we wanted to 
circumvent the methodological challenges associated with sample characteristics, as 
highlighted by Shekleton et al. (2012). This provides the opportunity to investigate the 
relationship between reports of sleep impairments and symptoms of insomnia in a relevant 
sample associated with both frequent reports of sleep impairment and physiological and 
cognitive alterations and variability. 
2.1 Research Questions and Hypothesis for Paper I 
Research questions: 
How does PE compare against CBT in patients with PD, with reference to both short-term and 
long-term effects, as well as clinically significant change? 
Hypotheses:
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H1: Based of the effects found in previous studies, we expected CBT to be more effective. 
2.2 Research Questions and Hypothesis for Paper II 
Research questions: 
Is vagally mediated HRV related to executive functioning in patients with PD, and are these 
psychophysiological measures related to key clinical variables? 
Hypothesis:
H1: Based on previous studies, we expected HRV to be positively related to measures of 
executive functioning. 
Due to few and inconsistent previous findings on the relationships between 
psychophysiological and clinical variables, these associations were assessed exploratory. 
2.3 Research Questions for Paper III 
Research questions: 
Is subjective sleep quality related to cognitive inhibition and vagally mediated HRV in 
patients with PD? 
As these relationships had not been assessed in PD-patients previously and only to a very 
limited extent in general, we had no pre-specified hypotheses for these research questions. 
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3.0 Methods 
3.1 Issues Overarching the PhD Thesis 
Participants in the project were assessed a total of five times (waves). These were at the initial 
contact (T1), just prior to treatment (pre-treatment; T2), immediately following treatment 
(post-treatment; T3), at six months follow-up (T4), and at the twelve months follow-up (T5). 
Outcome measures were assessed on all waves. For theoretical and practical purposes 
measures of physical fitness, HRV and neuropsychological measures were assessed at T2 and 
T3. Both T1 and T2 are baseline-assessments, as they were both conducted prior to treatment. 
As explained in section 3.2.1, the interval between T1 and T2 was related to the recruitment 
of patients to the RCT, and the outcome assessment at T2 was conducted to monitor clinical 
stability before treatment initiation. However, in Paper I, T1 is referred to as ‘baseline’, and 
T2 is referred to as ‘pre-treatment’, whereas in Paper II and III T2 is referred to as baseline. 
Paper I is based on measurements from all T1-5, while Paper II and III primarily investigate 
measures obtained at T2. 
3.1.1 Missing data 
Single items missing within inventories amounted to 0.12% of the total number of 
observations. Total or mean scores on primary and secondary outcome measures across the 
five waves that were missing due to lacking responses from participants or administrative 
error amounted to 7.14% of all observations. 
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3.2 Paper I 
3.2.1 Sample and procedure 
Individuals between the ages of 18 and 50 years that met the diagnostic criteria for PD with or 
without agoraphobia according to the Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV-TR; APA, 2000) were recruited. Exclusion criteria comprised the following: 
Psychotic disorders, substance-abuse, including the habitual use of benzodiazepines, severe 
major depressive episode, medical conditions that preclude participation in physical exercise, 
or organic brain disorder. Exclusions according to the first three criteria were established with 
the Structured Clinical Interview for DSM-IV axis I Disorders (SCID-I; First, Spitzer, 
Gibbon, & Williams, 1995), whereas the last two criteria were determined through interview 
with the participant, and when necessary, by consulting with the participant’s general 
practitioner (GP). All participants were also assessed with the Structured Clinical Interview 
for DSM-IV Axis II Personality Disorders (SCID-II; First, Spitzer, Gibbon, Williams, & 
Benjamin, 1994).
 The project was implemented within a district psychiatric centre (DPS), and in an aim 
to recruite a clinically valid and relevant sample for treatment in secondary care, all (n = 60) 
general practitioners, psychologists and psychiatrists in the centres region were invited to 
participate in the study by referring relevant patients for treatment in the project. 19 out of 60 
of these professionals registered to cooperate with the project. The main primary health care 
providers cooperating with the DPS were also briefed about the treatment project, and 
routines for referring subjects for participation were provided. Patients could also be referred 
from the centres own outpatient clinic as well as from the section for inpatients. However, this 
all resulted in few referrals, and the majority of participants were eventually recruited through 
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advertisements in the local press (83%). Recruitment took place from May 2007 till August 
2008, and final assessment was completed in January 2010. 
The study was conducted within a day-care unit. This unit had a staff of nine, and 
provided a minimum of 1550 patient-days (days * patients) per year. The unit routinely 
delivered group treatment primarily for patients referred with a primary diagnosis of anxiety 
or depression, and CBT and PE were key components in this treatment.
 141 people contacted the project, and initial eligibility was established by telephone. 
Sixty-six potential participants underwent a diagnostic interview on site, and 36 of these were 
finally randomised to either of the two interventions according to an electronically 
(http://www.randomizer.org) matched pairwise procedure based on sex and scores on the 
Beck Anxiety Inventory (BAI; Beck & Steer, 1993). 17 participants were randomised to PE 
and 19 to CBT.
Participants had a mean age of 37.9 years (SD = 8.6), and had suffered from PD for a 
mean duration of 10.1 years (SD = 9.5). More than a third of the sample (38.9%) had 
previously sought treatment for PD or symptoms of PD. Furthermore, 36.1% used an SSRI, 
and 13.9% had used benzodiazepines intermittently during the last month. The majority of 
participants (80.6%) were female and 27.8% reported living alone. Almost half of the sample 
(47.2%) was in full-time employment six months before inclusion to the study, and 19.4% of 
participants were in rehabilitation programs, on sick leave or without regular work. Mean 
Body Mass Index (BMI) was 26.7 (SD = 5.8). A majority (80.6%) of participants had 
agoraphobia, and 38.9% of the sample was depressed. Not counting agoraphobia, participants 
were diagnosed with a mean of 2.1 additional co-morbid axis-1 disorders and 0.4 axis-2 
disorders. All participants were screened for risk-factors related to CHD (i.e. a family history 
of CHD, hypercholesterolemia, diabetes, hypertension or smoking) in co-operation with a 
cardiologist, and four participants (11% of the sample) were referred for a cardiac evaluation 
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before the start of treatment. None of the participants had a history of myocardial infarction or 
CHD.
No significant differences were found between the participants in the two treatment 
groups (i.e. CBT and PE) on the characteristics listed above. Neither were they found to differ 
on any of the outcome measures prior to treatment, nor on the measures of physical fitness or 
reports on levels of ongoing PE. Bonferroni-corrected within-groups comparisons did not 
indicate any significant changes from baseline (T1) to pre-treatment (T2) for the participants 
in the two treatments.
Participants were requested to stabilize use of psychotropic medication during the 
treatment period and 2 weeks before and after this period, and use of such medication was 
monitored throughout participation in the study and confirmed via patient self-report. Each 
participant’s use was converted to daily doses, and one-way repeated measures ANOVAs 
including all five assessments indicated that levels of medication remained stable for 
participants in both the PE group, F(2.59, 41.41) = 1.58, p = .213 (Huynh-Feldt correction) 
and the CBT group, F(1.70, 30.55) = 0.48, p = .593 (Huynh-Feldt correction). 
As the treatments were performed in groups, a sufficient number (twice the maximal 
group size, i.e. 16) of participants had to be recruited before randomisation and treatment 
could be implemented for each round. This meant that participants had to wait a variable 
period depending on the time of their recruitment, with a mean of 68 days for the total sample, 
before the pre-treatment (T2) assessment and treatment initiation took place. Only one 
participant dropped out during treatment (from CBT), and one and four participants in the PE 
group and in the CBT group were not assessed at the 6-month follow-up, respectively. Three 
participants in both the PE-group and in the CBT-group were not assessed at the 12-month 
follow-up. Notably, when these follow-up assessments are viewed together, only one and two 
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participants were not assessed in either of the follow-up assessments for PE and CBT, 
respectively.
3.2.2 The interventions 
The treatments lasted 12 weeks, and were administered in groups of maximum 8 participants. 
One booster session was offered three months following the end of treatment.
3.2.2.1 Therapists and treatments 
PE. PE was supervised by an experienced team of three: one specialized 
physiotherapist, one occupational therapist, and one psychiatric nurse, and two members of 
this team were always present during sessions. Sessions were performed three times per week, 
with three different types of sessions repeated weekly on set days. On these days the PE either 
focused on i) increasing aerobic fitness through long-distance running (initially walking) and 
interval training, ii) increasing muscular strength through circuit training, and iii) performing 
exercises that had varied intensity, including competitive games. Each session lasted 
approximately 1.5 hours, including introduction, warm up, stretching and debriefing. 
PE was administered in accordance with a manual designed at the clinic. This manual 
was based on recommendations from previous research on PE with anxious subjects 
(Martinsen, Hoffart, & Solberg, 1989; Meyer & Broocks, 2000; Petruzzello et al., 1991; Stein 
et al., 1992), and for healthy adults (Haskell et al., 2007; Pollock et al., 1998). A pilot was 
conducted to ensure the practical and motivational properties of the manual.
In accordance with recommendations (Meyer & Broocks, 2000), participants were 
briefed initially regarding the physical sensations they might experience during exercises and 
the similarity of these to symptoms of anxiety. Session attendance was monitored, and 
participants in PE had a mean attendance rate of 88.7% (SD = 10.0) for the treatment sessions. 
When prohibited from participating in a given session, participants were instructed to perform 
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an equivalent exercise, and to record this on a provided form. This was however not registered 
as treatment attendance. 
CBT. CBT was supervised by an experienced team of two specialists in clinical 
psychology with post-graduate qualifications and extensive experience with group treatment. 
The CBT was administered according to a manual developed by the treatment team. This 
therapy was based on the treatment model for PD developed by David Clark and colleagues 
(Clark, 1986; Clark et al., 1994; 1999), and was customized for group sessions. Both 
therapists were always present during the sessions that lasted approximately 2 hours. Every 
session also included a brief assessment of symptom severity and evaluation and planning of 
homework. Sessions were administered once a week, with an attendance rate of 86.0% (SD = 
23.6), quite comparable to what was reported for PE above. 
3.2.2.2 Treatment fidelity 
CBT served as the evidence based control condition in the present study, and additional 
measures were taken to control the quality of this intervention. Six treatment-sessions were 
therefore randomly selected, evaluated and rated on site by a competent observer (a specialist 
clinical psychologist that was formally qualified as a supervisor of cognitive therapy by the 
Norwegian Association for Cognitive Therapy). Quality of the CBT was scored on the 
Cognitive Therapy Adherence and Competence Scale (CTACS; Barber, Liese, & Abrams, 
2003; please refer to section 3.2.3.3 for description), and the random selection of sessions 
covered half of total treatment content, with sessions drawn from both the initial and final 
stages of the treatment period. Between sessions, the treatment team received supervision 
from a different supervisor of cognitive therapy (also qualified by the Norwegian Association 
for Cognitive Therapy). 
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CTACS-ratings indicated that both the content and manner of delivery of the CBT was 
highly satisfactory, with means scores of 4.7, 4.3, and 4.8 for competence, adherence, and 
overall performance of the therapists, respectively.
3.2.3 Measures 
All outcome measures presented below were adapted from English to Norwegian by a 
translation-back-translation procedure. 
3.2.3.1 Primary outcome measures 
Agoraphobia. Agoraphobic cognitions and avoidance were measured using the 
Agoraphobia Cognitions Questionnaire (ACQ; Chambless, Caputo, Bright, & Gallagher, 
1984) and the Mobility Inventory (MI; Chambless, Caputo, Jasin, Gracely, & Williams, 
1985), respectively. The ACQ is considered to be a measure of fear of fear, and its 14 items 
that assess the frequency of thoughts common in agoraphobia are all rated on a scale ranging 
from 1 (thought never occurs when I am nervous) to 5 (thought always occurs when I am 
nervous). The Cronbach’s alpha for ACQ at baseline in the present study was .75. The MI is a 
27-item inventory assessing the frequency of avoidance for different situations relevant to 
daily life. It is comprised of two subscales that assess avoidance for these situations when 
subjects are alone and when they are accompanied, and items are rated on scales ranging from 
1 (never avoid) to 5 (always avoid). The subscales of MI are henceforth referred to as MI-
Alone and MI-Accompanied, and these subscales provide estimates of the individual’s actual 
freedom of movement, and therein their level of recovery through treatment. As agoraphobics 
generally feel safer together with a trusted companion, the MI-Alone normally obtains a 
higher average score than the MI-Accompanied (Chambless et al., 1985). In the present study 
MI-Alone is part of the criterion for evaluating clinically significant change. Cronbach’s 
alphas at baseline for MI-Alone and MI-Accompanied were .91 and .88, respectively. 
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Bodily sensitivity. Fear of bodily sensations was measured with the Body Sensations 
Questionnaire (BSQ; Chambless et al., 1984). This is a 17-item inventory of sensations that 
can be experienced during anxiety or when in a feared situation. Items are rated on a scale 
ranging from 1 (not at all frightened by this sensation) to 5 (extremely frightened by this 
sensation), and the Cronbach’s alpha at baseline for the BSQ in the present study was .87. 
Panic Attack Scale. Participants rated panic frequency and panic-related distress and 
disability on a 5-point scale ranging from 0 (no panic attacks) to 4 (one or more panic attacks 
per day) and on a 9-point scale running from 0 (not at all disturbing) to 8 (very disturbing),
respectively. These domains were also rated on an equivalent scale by a clinical psychologist 
(the first author, AH). This procedure is equivalent to what is described by Clark et al. (1994, 
1999).
3.2.3.2 Secondary outcome measures 
General anxiety. General anxiety was assessed with the BAI and the State-Trait 
Anxiety Inventory (STAI; Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983). The BAI 
consists of 21 items that describe subjective, somatic, or panic-related symptoms. Items are 
rated on a scale ranging from 0 (not at all) to 3 (severely – I could barely stand it), and 
Cronbach’s alpha at baseline for the BAI was .89. The STAI comprises two 20-item scales 
that assess both state and trait levels of anxiety. Subjects rate how much each item applies to 
them on a scale ranging from 1 (not at all) to 4 (very much). The STAI-S (state) lists 20 
statements referring to the anxiety and tension one experiences at the current moment, while 
the STAI-T (trait) lists 20 statements regarding the degree of anxiety and tension one feels in 
general. Cronbach’s alpha at baseline for both the STAI-S and the STAI-T was .91.
Depression. Level of depression was assessed using the Beck Depression Inventory II 
(BDI-II; Beck, Steer, & Brown, 1996). This inventory is comprised of 21 items, and severity 
40
of the different symptoms is rated on a 4-point scale (0-3). The Cronbach’s alpha at baseline 
for the BDI-II was .87.
Quality of life. Participants quality of life was assessed with the Quality of Life 
Inventory (QoLI; Frisch, Cornell, Villanueva, & Retzlaff, 1992). This inventory assesses 16 
different areas of life. Each area is rated on two scales; one for the importance of the 
particular area to the individual (rated on a 6-point scale ranging from -3 to 3), and one for the 
individual’s level of satisfaction with the area in question (rated on a 3-point scale ranging 
from 0 to 2). Scores for each area is made up by the product of the scores on these two scales. 
Areas rated with zero on importance were not included in the overall mean (ranging from -6 
to 6). The Cronbach’s alpha at baseline for the QoLI was .80. 
3.2.3.3 Additional measures 
Quality of therapy. Quality of therapy was measured with the CTACS. This is a 21-
item rating scale that assesses the quality of cognitive therapy. It covers both adherence to a 
therapy manual and the competence of therapy delivery. Items are rated from 0 (poor) to 6 
(excellent). A mean score is calculated for each domain, and one item specifically assesses the 
therapist’s overall performance. The Cronbach’s alpha across the 6 ratings in the present 
study was .93 for both the adherence and competence items.
Six-minute walk test. Physical fitness was assessed with the 6-minute walk test 
(6MWT; Enright, 2003). This is a self-paced measure of sub-maximal functional capacity, 
where subjects are instructed to walk, and not run, as far as possible within 6 minutes. 
Assessment in the current study was administered according to guidelines (Crapo et al., 
2002), using a corridor of 12.5 meters. 
The outcome measures listed in the preceding sections were administered on all five 
waves; T1-T5, with the exception of the clinician rated version of the Panic Attack Scale that 
was not rated at 12-month follow-up (T5), as this last follow-up assessment was conducted 
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via postal mail. Two additional questions were added to this last assessment. These questions 
pertained to treatment-seeking behaviour and changes in medication with reference to the year 
following the treatment period. These were phrased in the following manner (here translated 
into English): 1) ’Have you entered into a new therapeutic treatment directed at your panic 
disorder following termination of the treatment in the study?’ and 2) ’Have you been 
prescribed new psychotropic medication directed at your panic disorder, or changed your 
current prescription, following the termination of treatment in the study?’. Participants were 
prompted to provide additional information if they responded positively to any one of these 
questions.
3.2.4 Statistical procedures 
Group differences on continuous variables were investigated using t-tests for independent 
samples, and the Fisher’s exact test was employed for categorical variables.
Intention-to-treat analyses were used on all outcome measures. Mean or total values 
that were missing in these analyses were replaced by the last observation carried forward 
(LOCF). Data were deemed invalid if more than 20% of items for an inventory lacked 
responses. Mean or total values were in such cases substituted by LOCF. 
To reduce the likelihood of a type I error, analyses were performed in two steps. 
Initially doubly two-way repeated measure MANOVAs were performed on the primary and 
secondary outcome measures to determine whether the treatments were significantly different 
over time (Time×Group). If significant differences were found according to this procedure, 
subsequent two-way (Time×Group) ANOVAs would be conducted on each measure included 
in the corresponding MANOVA. One MANOVA was performed for each of the following 
constellation of inventories and rating scales: (1) the inventories MI-Alone, MI-Accompanied, 
ACQ, and BSQ, (2) self-rated and (3) clinician rated items on the Panic Attack Scales, and (4) 
all secondary outcome measures. Bonferroni-corrected within-groups effects with reference to 
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baseline values (T1) were investigated using t-tests, and effect-sizes are reported as Cohen’s 
d, calculated using pooled standard deviations (Cohen, 1988). 
 Reliable and clinically significant changes were investigated as recommended by 
Jacobson and Truax (1991). Change and recovery was based on changes in panic frequency 
and scores on the MI–Alone. Thus, a participant had reliable change if change on the MI-
alone exceeded the calculated Reliable Change Index. Clinically significant change was 
assessed with method C as referred to in Jacobson and Truax (1991), where a midpoint 
between the normal and the clinical population is estimated. Subjects with reliable change, 
and whose scores fall closer to the mean of the normal population than the clinical population, 
are considered to have changed clinically significant. However, for a subject to be considered 
recovered, the additional criterion of having zero panic attacks during the last 2 weeks prior to 
assessment must also be fulfilled. 
3.3 Paper II 
3.3.1 Sample 
The sample in this study consists of the same participants that are described in section 3.2.1 
under Paper I. The current study investigated these participants prior to treatment and 
randomisation. All measures reported in the current study were obtained at T2 except duration 
of PD that was assessed at T1. 
3.3.2 Procedure 
The sample was recruited according to the procedures described for Paper I (please refer to 
section 3.2.1). As described here, participants waited a mean of 68 days (range: 7-138 days; 
i.e. from T1 to T2) following the SCID-assessment before HRV and the neuropsychological 
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and clinical measures in the current study were administered. As described under section 
3.2.1, within-groups comparisons indicated that neither of the treatment groups changed 
significantly from T1 to T2.
 Assessments of HRV and neuropsychological measures were conducted on separate 
occasions and in different clinics. With reference to distance of travel, some participants 
preferred to complete both assessments on the same day, whereas others conducted the 
assessments within the timeframe of a few days. 
3.3.3 Measures 
3.3.3.1 HRV 
HRV measures were obtained using a three-lead electrocardiogram (ECG) acquired with an 
ambulatory monitoring system (VU-AMS; (de Geus, Willemsen, Klaver, & van Doornen, 
1995). ECG sampling rate was 1000 Hz, and the Ag/AgCl electrodes (1700 CleartraceTM,
Conmed, Utica, NY) were placed below the right clavicle, 4 cm to the right of the sternum; on 
the right side between the two lower ribs; and under the left breast, 4 cm below the nipple. 
The recording session lasted approximately 20 minutes, and was conducted individually in a 
quiet location with an investigator available. As recommended by Yeragani et al. (1993), 
ECG was recorded while participants were standing.
Visual QRS-detection was performed with the aid of the ECG QRS scoring utility 
(version 1.0.5.8; Vrije Universiteit van Amsterdam), and further analyses of the HRV 
measures were conducted with the Kubios HRV (version 2.0; University of Eastern Finland). 
In order to ensure a stable and artefact-free recording, the first and last 30 seconds of the five 
minute recordings were excluded yielding a stable 4-minute recording for each subject. 
Artefact corrections were kept at a minimum by consulting with the corresponding ECG 
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signal for each recording. Trend components were removed using the smoothness priors 
method (Tarvainen, Ranta-Aho, & Karjalainen, 2002) available in the Kubios HRV software. 
High frequency (HF) HRV, based on HF-power (ms2), was used as measure of vagally 
mediated HRV (Malik et al., 1996). HF-power (ms2) estimates were derived from an 
autoregressive algorithm with a standard model order of 16 and a frequency-band of 0.15-0.40 
Hz. The root mean squared successive differences (rMSSD) time domain measure and HR 
were used as secondary cardiac indices. Both HRV measures were transformed to their 
natural logarithms. As HF HRV and rMSSD were significantly correlated (r = .90, p < .01), 
only HF HRV was used to assess the relationships with neuropsychological measures. 
3.3.3.2 Neuropsychological measures 
The Wisconsin Card Sorting Test (WCST) and The Color-Word Interference Test (CWIT) 
from the Delis-Kaplan Executive Function System (D-KEFS; Delis, Kaplan, & Kramer, 2001) 
were used as measures of executive functioning. Both measures were assessed at a university-
based neuropsychological polyclinic by a professional test-technician. 
In the current study a computerised version of the WCST; Wisconsin Card Sorting 
Test: Computer Version 4 research edition (WCST: CV4; Heaton, PAR Staff, & Goldin, 
2003) was used. The scoring procedures of this instrument are in accordance with the 
principles of the original WCST. Still, as recommended the test technician was also familiar 
with the original version of the WCST. This assessment provided T-scores adjusted for age 
and education level for Total errors, Perseverative responses and Perseverative errors.
 The CWIT consists of four conditions: In Color naming, participants name the colours 
of coloured patches. In Word reading, participants read the names of colours printed in black 
ink. In Inhibition, participants name the colour of the ink that the different colour names are 
printed in when the ink and words are incongruous. In Switching (i.e. Inhibition/Switching), 
participants either read the words when the words are presented in a box or the name of the 
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colour the words are written in when the box is not present. The first three conditions are 
equivalent to the original Stroop (Stroop, 1935), and the additional Switching condition is 
intended to measure cognitive flexibility and complex attentional shifting. The first two 
conditions are control conditions. Age-adjusted scaled scores, with a mean of 10 and a 
standard deviation of 3, are provided for all four conditions with regard to the time needed to 
complete the task. For Inhibition and Switching the test also provides scaled scores for the 
total number of errors committed. Higher scores indicate better performance. 
 Both the Stroop and the WCST are considered prototypical measures of cognitive 
inhibition and attentional shifting, respectively (Myiake et al., 2000). Cognitive inhibition 
here refers to the definition offered by Myiake et al., and “concerns one’s ability to 
deliberately inhibit dominant, automatic, or prepotent responses when necessary” (2000; pp. 
57). Attentional shifting refers to the ability of “shifting back and forth between multiple 
tasks, operations, or mental sets” (Myiake et al., 2000; pp. 55). In a latent-variable analysis 
Myiake et al. (2000) found these two executive functions, together with the ability to update 
and monitor working memory, to constitute key executive functions, underlying other 
executive functions. 
3.3.3.3 Clinical measures 
The following clinical measures were used in this study: ACQ, MI, BSQ, BAI, STAI-T, and 
Chronbach’s alphas at T2 for these measures were .72, .91, .85, 91, and .93, respectively. 
Panic frequency and panic-related distress and disability (henceforth referred to as Panic-
related distress) from the Panic Attack Scale were also assessed. All of the above measures 
have been described in section 3.2.3.1 and 3.2.3.2 of Paper I. Panic duration (i.e. duration of 
PD) was obtained during the SCID-I assessment at T1. 
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3.3.4 Statistical procedures 
All analyses were conducted using PASW (SPSS) version 17.0. Pearson’s r was used to 
investigate correlations and partial correlations between continuous variables. Kendall’s tau
(W ; Howell, 2012) was used to assess associations that included the Panic frequency and 
Panic-related distress variables, as these short scales yielded many tied ranks. With reference 
to the hypothesised directional relationship between HF HRV and the neuropsychological 
measures of executive functioning, the significance of these questions was assessed with one-
tailed tests (Ferguson & Takane, 1989). All other tests were two-tailed.
3.4 Paper III 
Sample and procedure is equivalent to Paper II. Please refer to sections 3.3.1. and 3.3.2. 
3.4.1 Measures 
3.4.1.1 HRV 
This measure is described under Paper II. Please refer to section 3.3.3.1. The current study 
only investigated the primary measure of vagally mediated HRV: HF HRV. 
3.4.1.2 Cognitive inhibition 
Cognitive inhibition was assessed with the Inhibition condition in the CWIT (henceforth 
referred to as the Stroop) from the D-KEFS (Delis et al., 2001). Please refer to section 3.3.3.2 
under Paper II for descriptions of the D-KEFS, the CWIT, and the Stroop. 
3.4.1.3 Measure of sleep impairment 
Sleep impairment was assessed with the Pittsburgh Sleep Quality Index (PSQI; Buysse, 
Reynolds, Monk, Berman, & Kupfer, 1989). This is a self-report questionnaire that assesses 
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sleep disturbances and sleep quality during the last month. It comprises 19 items that yield 
seven component scores: Sleep quality, Sleep latency, Sleep duration, Habitual sleep 
efficiency, Sleep disturbances, Use of sleep medication and Daytime dysfunction. The sum of 
these components yields the global PSQI score. Higher scores indicate poorer sleep, and cut-
off for global score above 5 provides maximum sensitivity and specificity for insomnia 
(Buysse, Ancoli-lsrael, Edinger, Lichstein, & Morin, 2006). Component scores range from 0-
3. Cronbach’s alpha for the PSQI was .77. 
3.4.1.4 Additional clinical measures 
The sample was assessed by the following clinical measures: BSQ, ACQ, BAI, STAI-T,
BDI-II. Chronbach’s alpha’s for these measures at T2 were .85, .72, .91, .93. 87, respectively. 
Panic frequency and Panic-related distress from the Panic Attack Scale were also used. These 
measures have all been described in section 3.2.3.1 and 3.2.3.2 under Paper I, and section 
3.3.3.3 under Paper II. 
3.4.2 Statistical procedures 
All analyses were conducted using PASW (SPSS) version 17.0. Pearson’s r was used to 
investigate all correlations and partial correlations. Partial correlations (r) were used to 
investigate whether relationships between sleep components and measures of cognitive 
inhibition and HRV were independent of depression. Thereafter, corrections for multiple 
comparisons between sleep components and measures of cognitive inhibition and HRV were 
performed with a modified Bonferroni procedure (Simes, 1986).
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3.5 Ethics 
All participants in the three studies were required to sign a written informed consent prior to 
enrolment, and the research project was approved by the Regional Committee for Medical and 
Health Research Ethics in Western Norway and by the Norwegian Social Science Data 
Services. The study is registered at ClinicalTrials.gov (identifier: NCT01076777). 
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4.0 Results 
Please refer to the attached corresponding reprints for tables, figures, and additional details. 
4.1 Paper I 
4.1.1 Between-groups effects 
4.1.1.1 Primary outcome measures 
The combined analysis of the four inventories (MI-Alone, MI-Accompanied, ACQ, and BSQ) 
revealed a significant effect of time from baseline to the 12-month follow-up, F(16, 544) = 
7.28, p < .01, as well as a significant Time×Group interaction, F(16, 544) = 1.71, p = .042. 
This indicates that the two treatments produced different treatment effects over time as 
assessed by the primary outcome measures.
 The subsequently conducted repeated measures ANOVAs also demonstrated a 
significant Time×Group effects for the MI-Alone, F(2.28, 77.61) = 3.75, p = .023, the MI-
Accompanied, F(2.19, 74.28) = 3.93, p = .021, and the BSQ, F(2.81, 95.43) = 4.08, p = .010, 
but not for the ACQ. 
 No significant differences between the interventions were found on the equivalent 
assessments of panic frequency and panic-related distress and disability, neither on the self-
report scales nor on the clinician-rated version. However, both versions revealed a significant 
effect of time, F(8, 272) = 15.48, p < .01, and F(6, 204) = 16.69, p < .01, respectively. 
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4.1.1.2 Secondary outcome measures 
The combined MANOVA performed on the five secondary outcome measures revealed a 
significant effect of time, F(20, 540) = 5.21, p < .01, but no significant Time×Group 
interaction.
4.1.2 Within-groups effects 
Bonferroni corrected post-hoc tests demonstrated significant results (p < .05) from baseline to 
the 12-month follow-up on all measures except the QoLI and the STAI-S for CBT. For PE, 
the equivalent analyses yielded significant results on the following measures: The MI-Alone, 
the ACQ, the BSQ, both the self-rated- and the clinician-rated versions of panic-related 
distress and disability, the BAI, and the BDI-II. 
4.1.3 Effect sizes 
Between-groups effect sizes were generally in favour of CBT, except the effect sizes for the 
STAI-S, the BDI-II and the QoLI. Within-groups effect sizes for PE were small to moderate 
on both the MI-Alone and the MI-Accompanied on all assessments following treatment 
termination. The equivalent assessments were all large on the ACQ and the BSQ. For CBT all 
effects were large on the corresponding outcome measures. Both treatments produced large 
effects on panic-related distress and disability following the treatment, although these effects 
were substantially larger for CBT. Assessments of reduction in panic frequency showed 
moderate effects for PE and large effects for CBT. Findings on these two latter measures were 
consistent across the self-report and clinician ratings.
Regarding secondary outcome measures, both interventions yielded large effects on 
both the BAI and the BDI-II for all assessments following treatment termination. The 
interventions also yielded moderate to large effects on the STAI-S, and small effects on the 
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QoLI. The interventions differed on the STAI-T, for which effects were large following CBT, 
while only moderate after PE. 
4.1.4 Reliable and clinically significant change 
12 months following treatment termination 63.2% of patients treated by CBT showed reliable 
improvement and 52.6% had a clinically significant change as measured by the MI-Alone. 
The equivalent values for PE were 35.3% and 11.8%, respectively. The rates of reliable 
improvement were not significantly different (p = .181, two-sided Fisher’s exact test) across 
the two treatments, but the difference in rates of clinically significant changes was (p = .014, 
two-sided Fisher’s exact test). Estimated recovery (e.g. freedom from panic attacks and 
clinically significant change) was 47.4% following CBT and 11.8% for PE (p = .031, two-
sided Fisher’s exact test). 
4.1.5 Treatment-seeking and change in psychotropic medication 
at 12-month follow-up 
Half (50%) of those participating in PE had entered new psychotherapy directed at their panic 
within 12 months following treatment termination, compared to none in the CBT group (p = 
.002, two-sided Fisher’s exact test). Also, three participants in the PE-group had either 
increased or been prescribed a new psychotropic medication directed at their panic, compared 
to one in the CBT group (p = .33, two-sided Fisher’s exact test). 
4.2 Paper II 
Results in this study demonstrated significant correlations (at p < .05) between HF HRV and 
the three subscores of the WCST; Total errors, Perseverative responses, and Perseverative 
errors, r = .37, r = .35, and r = .34, respectively. HF HRV also correlated significantly with 
52
both time and errors on the Inhibition condition from the CWIT, r = .30, p < .05, and r = .43, 
p < .01, respectively. 
 Significant associations (at p < .05) were found between Panic-related distress and 
both errors committed on the Inhibition condition and HF HRV, W = .27, and W = .29, 
respectively. Equivalently, Panic duration and both time spent on the Inhibition condition and 
HF HRV were found to be related, r = .37, p < .05, and r = .45, p < .01, respectively.
As found in previous studies (Schwartz, Gibb, & Tran, 1991), HF HRV correlated 
negatively with age, r = -.41, p < .013. Partial correlations controlling for age found HF HRV 
to be significantly correlated with Panic duration also when the participant’s age was 
controlled for, r = -.34, p < .047. 
4.3 Paper III 
Two-thirds (69.4%) of the sample had a global PSQI score compatible with the presence of 
insomnia (i.e. index > 5; Buysse et al., 2006). Depression was found to be positively related to 
the global PSQI score (r = .43, p = .008), and the components Sleep disturbances (r = .41, p =
.014), Use of sleep medication (r = .45, p = .005), and Daytime dysfunction (r = .48, p =
.003). Scaled scores for time and errors on the Stroop were also significantly but inversely 
related to the global PSQI score, r = -.35, p = .037 and r = -.35, p = .041, respectively. 
Furthermore, these correlations were also significant after controlling for the level of 
depression, r = -.36, p = .036 and r = -.39, p = .019, respectively. Regarding the different 
components of the PSQI, both scaled scores for time and errors on the Stroop were inversely 
related to scores on both Sleep quality, r = -.34, p = .041 and r = -.37, p = .027, respectively, 
and Sleep latency, r = -.40, p = .017 and r = -.41, p = .013, respectively. Both errors on the 
Stroop and HF HRV correlated significantly and negatively with Sleep disturbances, r = -.37, 
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p = .027, and r = -.43, p = .008, respectively. Also these relationships retained significance 
following control for the level of depression, r = -.41, p = .015 and r = -.43, p = .010, 
respectively. However, after controlling for multiple comparisons using the Simes procedure, 
cognitive inhibition was no longer significantly associated with the global PSQI score and 
Sleep quality. 
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5.0 Discussion 
5.1 Main Findings 
5.1.1 Physical exercise for panic disorder 
We found that CBT was significantly better than PE over time as assessed in the combined 
analysis of the four primary outcome inventories. Although analyses of the other primary and 
secondary outcome-measures indicated no difference between the treatments over time, 
effects following CBT were almost exclusively larger than the effects from PE, and CBT also 
yielded a larger proportion of significant changes from baseline to any of the assessments 
following treatment. These findings are corroborated by the differences in clinically 
significant change and treatment seeking behaviour within one year after treatment.
 The effects found for PE in the current study are not surprising with reference to the 
study by Broocks et al. (1998), where PE was also found to yield large post-treatment effects. 
The important contribution of the current study is the demonstration that this effect is also 
present one year following treatment termination. Furthermore, the current study also 
indicates that such changes following PE are not necessarily sufficient to provide clinically 
significant changes or remission from PD. Regarding CBT, it had already been demonstrated 
that treatment effects were retained for at least a year (Clark et al., 1994; 1999). None of the 
previous randomised studies on PE for PD included long-term follow-up (Broocks et al., 
1998; Wedekind et al., 2010), but the current results are at odds with the findings in the 
naturalistic study by Martinsen et al. (1989), where the changes for patients with PD were 
non-significant at the one year follow-up. Although CBT generally yielded larger and more 
consistent effects, the effects following from PE were large. The finding that these changes 
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persist, or continue, over the next year is noteworthy, especially as subjects were not 
specifically instructed to continue PE after treatment.
Among the primary outcome inventories, effects from PE were smallest on the 
measure assessing agoraphobic avoidance (MI), and it could be argued that the assessment of 
clinically significant effects was rigged in the favour of CBT. CBT for PD is directly targeted 
at cognitive misinterpretations of bodily symptoms, and at challenging the patient’s thoughts 
and conclusion regarding these. However, CBT also works directly on agoraphobic 
avoidance, and subjects are directed to challenge their own expectations and their fear during 
in vivo exposures. This exposure mainly takes place as homework between sessions, but when 
necessary, by use of guided in-situ exposure. This was also the case in the current study. PE, 
on the other hand, does not have this element of directed guidance towards exposure. Still, the 
gold standard for assessing clinically significant change for PD are the ones pertained to in the 
current study (Baillie & Rapee, 2004), and this also makes sense from a clinical perspective. 
In order to be cured of PD one must both be free from panic attacks, as well as have improved 
substantially in terms of freedom of movement. When considering the changes resulting from 
PE, it appears that large changes had taken place in subjects regarding both the interpretation 
of bodily symptoms, and cognitions on agoraphobic fear. However, without the element of 
guided exposure, these changes in thought did not appear to manifest themselves into changes 
in overt behaviour. Thus, PE alone does not appear to be a sufficient treatment for PD, 
contrary to what has been suggested (Asmundson et al., in press; Otto et al., 2007; Smits, 
Powers, Berry, & Otto, 2007).
5.1.2 Panic disorder, HRV and executive functioning 
The current study demonstrated that key executive functions were related to vagally mediated 
HRV. The results also indicated that measures of panic severity and duration can be related to 
both measures of executive functioning and vagally mediated HRV. Based on previous 
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research on healthy subjects (Hansen et al., 2004; Hansen et al., 2003; Mathewson et al., 
2010; Richards & Casey, 1991; Suess et al., 1994) and the study on dental phobics (Johnsen 
et al., 2003), we expected to find a positive relationship between the executive measures and 
HRV. These findings were here consistent and selective, and there was no significant 
relationship between the non-executive control conditions Word reading and Color naming. 
The lack of association between the Switching condition and HRV was not expected, 
however. According to Delis et al. (2001) Switching is a measure of attentional shifting, 
supposedly requiring the ability for set shifting in addition to cognitive inhibition, and Delis et 
al. (2001) cite significant associations between this condition and perseverative errors on the 
WCST. However, according to Lippa and Davis (2010), Switching could in fact be less 
demanding, due to the increased proportion of word reading in this condition. They further 
found this to be particularly relevant for young subjects, a characteristic that could have 
relevance for a substantial proportion of the current sample. As such, it is possible that the 
Switching condition was not sufficiently demanding to require an executive ability related to 
vagally mediated HRV in the current sample.
 The immediate implications of the current findings are that baseline or resting levels 
of vagally mediated HRV are related to executive functioning across a broad spectrum of 
conditions, from healthy to anxious subjects. It is also important that HRV was assessed at 
baseline, and is thus independent of possible cardiac responses elicited by the 
neuropsychological assessment itself. This means that the current associations reflect a tonic 
HRV state in these patients, and provides support for the hypothesised relationship between 
vagally mediated HRV and activity in areas in the PFC (Thayer et al., 2012). As executive 
functions, and especially those assessed here, are related to cognitive flexibility (Rossi et al., 
1997), this furthers the case for those suggesting HRV to be a non-invasive marker of flexible 
functioning (Appelhans & Luecken, 2006; Kashdan & Rottenberg, 2010; Thayer & Friedman, 
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2002). It also implies that both mental health and cognitive functioning are related to cardiac 
regulation and cardiac health. 
 The associations found between clinical variables and both HRV and executive 
measures are interesting, although they should be treated with caution due to the exploratory 
nature of these results. The findings do however replicate and extend previous findings. Both 
HRV and cognitive inhibition were found to be negatively associated with measures of PD 
severity. Cognitive inhibition has been found to be negatively associated with anxiety 
(Eysenck et al., 2007), or impaired in the presence of PD (Dupont et al., 2000). Thus the 
negative association found here between cognitive inhibition and Panic-related distress is 
compatible with those previous findings, and indicates that cognitive inhibition is also related 
to experienced severity of PD. As PD is characterised by decreased HRV, it could also be 
expected that HRV is associated with PD severity (i.e. Panic-related distress). Nonetheless, 
previous assessments in this area have been both scant and inconclusive (Alvarenga et al., 
2006; Yeragani et al., 1990; Yeragani et al., 1993), and the current findings suggest that this 
should be further investigated. We also found Panic duration to be related to both HRV and 
cognitive inhibition. The question that naturally arises is whether longer duration of PD leads 
to decreased HRV and relatively impaired cognitive inhibition, or vice versa. This is further 
discussed under section 5.2 Psychophysiology in Panic Disorder. 
5.1.3 Panic disorder, inhibition and sleep 
The current study found cognitive inhibition to be related to key constructs regarding the 
development and persistence of insomnia and sleep impairment (Espie, 2002; Perlis et al., 
1997). This supports the psychobiological inhibition model of insomnia (Borbély, 1982; 
Espie, 2002), and extends previous findings on the relation between cognitive inhibition and 
sleep impairment (Bastien, 2011; Bastien et al., 2008). Bastien et al. (2008) found ERPs 
measuring cognitive inhibition to be related to sleep onset latency. The current study found a 
58
different measure of cognitive inhibition (i.e. results on the Stroop) to be related to both sleep 
initiation (Sleep latency) and sleep maintenance (Sleep disturbances). Importantly, the current 
findings were independent of level of depression. 
 HRV was also found to be related to Sleep disturbances. This could mean that HRV 
reflects neuronal inhibition in the PFC that can be related to sleep impairment. Still, the 
interpretation of this finding is somewhat less straightforward. Sleep disturbances was the 
only sleep component that HRV was found to be related to, and even though this relationship 
was strong, the result regarding the relationship between HRV and the different components 
of the PSQI is overall less consistent than what was found for cognitive inhibition. 
Furthermore, there is a likely alternative explanation for this relationship. Stein et al. (1993) 
found patients with PD to differ from controls on Sleep disturbances. As Sleep disturbances is 
a multifaceted component comprising a variety of disturbances, those authors explored which 
disturbance patients with PD and controls differed on. They found patients with PD to report 
significantly more disturbances on the item ‘Cannot breathe comfortably’. It should here be 
noted that some measures of HRV are known to be related to subjects’ breathing frequencies. 
However, it has recently been shown that the method for assessing vagally mediated HRV 
utilised in the present study is a robust measure against respiratory influence (Lewis et al., 
2012). Thus, it is unlikely that the relationship between the current HRV measure and Sleep 
disturbances was mediated primarily by subjects’ breathing pattern. However, nightly panic 
attacks is a characteristic feature of PD (APA, 2000), and the relationship in question could 
reflect the relatively decreased HRV found in patients suffering from such nocturnal panic 
attacks (Sloan et al., 1999). This means that patients with nightly panic attacks report more 
disturbances during sleep, while these same patients also have relatively reduced HRV 
compared to patients that do not experience these nightly attacks.
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Yang et al. (2011) found an association between HRV and the global PSQI score in 
depressed patients, but not in insomniacs. In the current study we did not find a significant 
association between the global PSQI score and vagally mediated HRV. The current findings 
thus add to the literature regarding HRV and subjectively reported sleep impairment within 
different group of patients.
5.2 Psychophysiology in Panic Disorder 
In addition to evaluate the clinical properties of PE as treatment for PD, the current thesis 
aimed to elucidate the psychophysiology in these patients. Patients with PD are known to 
have altered physiological regulation in terms of impaired vagally mediated cardiac control. 
As presented in section 1.4, it has been suggested that decreased vagally mediated HRV 
reflects reduced neuronal inhibitory activity in areas in the PFC associated with executive 
functioning. Furthermore, it has been established that the heart and these areas in the PFC are 
linked anatomically, and that activity in these areas is related to vagally mediated HRV. 
Studies have also shown that vagally mediated HRV is related to executive functioning in 
healthy subjects. Such a relationship had however not been previously documented in patients 
with PD, the group of anxiety patients most consistently characterised by decreased vagally 
mediated HRV.
5.2.1 Psychophysiology and the development of panic disorder 
Thayer et al. (2009) have suggested that decreased HRV constitutes a vulnerability for the 
development of psychopathology, due to the associated altered functioning of the PFC. 
Furthermore, when the state of anxiety has developed in the individual, these cognitive and 
physiological changes perpetuate the clinical condition due to the impact the decreased 
cognitive flexibility has on reasoning, functioning and appraisal of situations and stimuli 
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(Brosschot, Gerin, & Thayer, 2006; Friedman, 2007; Thayer & Friedman, 2002; Thayer & 
Lane, 2000). The current findings indicated that both duration of the disorder, and the distress 
experienced from it were related to both of the investigated domains of psychophysiology; 
executive functioning and vagally mediated HRV. As mentioned in section 5.1.2, the results 
from the study in the current thesis can only indicate that there is a relation between the 
variables in question. However, the directionality and clinical relevance of these findings 
regarding the development and persistence of PD could be more evident when these findings 
are considered together with previous studies and theoretical developments.
The altered functioning in the PFC is thought to result from experienced stress (Thayer 
et al., 2009). This is further suggested to lead to a concomitant decrease in vagally mediated 
HRV and changes in executive functions related to this part of the brain. Stressful life events 
are linked to the development of PD (APA, 2000). The questions are thus: Do stressful life 
events lead to reduced inhibitory activity in the PFC with concomitant decreased in vagally 
mediated HRV and altered executive functioning that increase the risk for the development of 
psychopathology like anxiety, or does such stress might result in anxiety which can then lead 
to the described physiological and cognitive changes? Melzig et al. (2009) found decreased 
HRV to result in increased startle potentiation for both healthy subjects and subjects with PD. 
Those authors even suggested that decreased HRV could be an endophenotype for the 
development of certain anxiety disorders. HRV has in the current thesis been demonstrated to 
be positively related to executive functioning also in patients with PD, and this relationship is 
known to exist also for a variety of different groups of healthy adults as well as children. 
According to Brosschot et al. (2006) it is the perseverative cognitive processing that 
reinforces the impacts of events on the individual. The results by Melzig et al. (2009) suggest 
that subjects with decreased HRV have increased apprehensive worry, and as vagally 
mediated HRV is positively associated with cognitive flexibility, these results appear to be in 
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line with Brosschot et al. (2006). Thus, the current relationship between Panic-related distress 
and both HRV and cognitive inhibition could be interpreted to indicate that level of distress is 
affected by these cognitive and physiological changes. This perspective can be complimented 
by the theoretical suggestions by Eysenck et al. (2007), who argue that the state of anxiety 
alters the executive functioning, and specifically the two executive functions addressed in the 
current thesis. These cognitive changes lead to the preferential processing of threat related 
stimuli, either internal or external in anxious subjects, and to a continuous search for threats 
when in the presence of neutral stimuli, either internal or external. When considering PD, this 
pattern seems compatible with the clinical presentation of this disorder, where patients are 
known to persistently monitor themselves for changes in body sensations or the avoidance of 
potentially threatening situations (i.e. where they can experience a panic attack). Thus, the 
altered executive functioning perpetuates and reinforces the appraisal of threat by the anxious 
individual so that the stressful state of anxiety persists, thereby sustaining the reduced 
inhibitory functioning in the PFC and the vicious cycle that renders anxiety a steady state.
As argued by Brosschot et al. (2006) perseverative cognitions mediate the transition 
from brief or temporary stress into a prolonged state of stress and possibly psychopathology. 
Based on this, it also seems most likely that the altered psychophysiology, as measures here, 
mediates prolonged duration of PD and not vice versa. As such, the associations found 
between psychophysiological and clinical variables in the current thesis can be interpreted 
within the presented theoretical notions and previous findings. They also extend previous 
findings by indicating that clinical developmental factors are related to these important 
psychophysiological variables. It should nonetheless be stressed that the current findings are 
exploratory and cross-sectional, and that these findings can merely highlight these issues and 
generate hypotheses as those presented above. More rigorous studies are needed to determine 
the directionality, and certainty of these relationships. 
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5.2.2 Psychophysiology and sleep in patients with panic disorder 
According to the psychobiological inhibition model, hyper-arousal in insomnia follows from 
impaired ability to inhibit wakefulness (i.e. arousal). As described in section 1.5.1, studies 
using ERPs have found cognitive inhibition to be related to key domains of sleep impairment. 
Anxiety, including PD, has been closely related to sleep impairment and insomnia. Insomnia 
is a highly frequent co-morbidity to PD, and anxiety disorders have both been suggested to 
share underlying characteristics with sleep disorders, and to precede the development of sleep 
impairment. If PD and anxiety are related to cognitive and physiological flexibility, it would 
be relevant to know how these constructs relate to a frequently co-occurring and possibly 
related co-morbidity such as sleep impairment.
The relationships between cognitive inhibition and sleep initiation and maintenance 
found in the current study can be interpreted in at least two ways: Cognitive inhibition is 
related to anxiety and worry (Eysenck et al., 2007). Worry either directly increases sleep 
latency and awakenings, or leads to increased arousal with the same consequences. 
Alternatively, cognitive inhibition is related to the ability to de-arouse, which is posited to be 
one of the main developmental and perpetuating mechanisms in insomnia and sleep 
impairment (Espie, 2002). Both of these explanations suggest a temporal developmental 
relationship between inhibitory control and sleep impairment. However, according to the first 
explanation, the relationship between cognitive inhibition and sleep is mediated by the 
development of anxiety. The developmental interrelations between anxiety, depression and 
insomnia are still a topic for discussion. However, studies have shown that the pervasive 
developmental pattern can be described to evolve from anxiety to insomnia and from 
insomnia to depression (Johnson et al., 2006; Ohayon and Roth, 2003). As anxiety is 
associated with impaired cognitive inhibition, and anxiety is considered to precede insomnia, 
this suggests that impaired cognitive inhibition could be an antecedent to the development of 
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sleep impairments and insomnia. As delineated above, this would also be in line with the 
psychobiological model of insomnia.
Previous research has found that impairment of inhibitory ability persists in depressed 
patients, irrespective of changes in level of depression (Årdal and Hammar, 2011; Biringer et 
al., 2007; Hammar et al., 2010). Equivalent results have been reported regarding insomnia and 
depression, where patients have been found to have residual sleep problems following 
remission from depression (Carney et al., 2007; Manber et al., 2003). Such residual sleep 
problems have even been found to be a predictor for repeated depression (Ohayon and Roth, 
2003; Reynolds et al., 1997). Persistence of sleep impairment and impaired cognitive 
inhibition following remission from depression could have many explanations. The perhaps 
most immediate suggestion pertains to the mentioned chronological interrelationship between 
anxiety, sleep impairment and depression. Thus, when depression is cured, anxiety, impaired 
cognitive inhibition, and also insomnia persist. Based on the current results and the argument 
presented above it could be suggested that the co-occurrence of persistent cognitive 
impairment and persistent sleep problems following remission from depression could be two 
sides of the same coin. Thus, the psychophysiological changes associated with PD addressed 
here can be related to developmental and perpetuating factors for insomnia and sleep 
impairments which frequently co-occur with PD. 
5.2.3 Psychophysiology and treatment effect of physical exercise 
for patients with panic disorder 
Previous knowledge on psychophysiology in these patients, and the sensitivity of measures of 
psychophysiology for PE provided an important part of the theoretical platform upon which 
the rational for providing PE as treatment for these patients was based.
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Both the current and cited previous findings indicate that PD is a severe anxiety 
disorder, characterised by alterations in behaviour, cognitive and physiological functioning, 
and mortality risk. Furthermore, these cognitive, and possibly also physiological, changes are 
related to frequently occurring co-morbidities found in PD (i.e. sleep). Psychotherapy has 
been found to result in increased HRV, thus possibly being cardioprotective for these patients 
(Friedman, 2007). The current findings both show that vagally mediated HRV is related to 
executive functioning in patients with PD, and that PE can provide a substantial and lasting 
reduction in key symptoms of PD. As described initially, the mechanisms behind the 
anxiolytic effects of PE are still not conclusively known. However, two different accounts of 
the clinical changes resulting from PE can be related to the mechanisms investigated here. In 
line with Solomon’s opponent-process model for motivation (Solomon, 1980), it has been 
suggested that the sympathetic activation accompanying PE leads to the opponent reaction of 
increased parasympathetic activation following exercise. Vagally mediated HRV is an index 
of parasympathetic activity, and HRV has been found to increase following PE (Coats et al., 
1992; Levy et al., 1998; Somers et al., 1991). Vagally mediated HRV is considered a measure 
of the organism’s adaptability (Appelhans & Luecken, 2006; Kashdan & Rottenberg, 2010), 
with reference to its close link with the PNS and cardiac regulation, as well as through the 
association with executive functioning. It is therefore interesting and noteworthy that research 
on the acute effects of PE indicates that this can result in increased mental flexibility as 
indexed by cognitive inhibition (Chang & Etnier, 2009), and that habitual exercise leads to 
improved executive functioning in both adults and older adults (Colcombe & Kramer, 2003; 
Smith et al., 2010). Furthermore, Hansen et al. (2004) found that abstaining from PE leads to 
both a decrease in executive functioning and decrease in vagally mediated HRV. This line of 
reasoning concurs with Salmon (2001), who argues that the beneficial effects of PE on mental 
health results from the organisms’ increased adaptability. 
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 As described in sections 1.3.1 and 1.3.2, the anxiolytic effects of PE have also been 
related to reduced fear of bodily sensations resulting from the exposure for these symptoms 
and sensations during PE. Fear of bodily sensations is a key construct in the cognitive model 
of panic (Clark, 1986; Salkovskis, Clark, & Hackmann, 1991). PE has also been found to 
reduce anxiety sensitivity effectively, and this construct has been shown to be an important 
predictor for the development of PD (Schmidt et al., 1999). However, according to the 
discussion above, the mechanisms behind the anxiolytic effect of PE could be discussed and 
investigated at a more fundamental level.
As PE appears to impact both cognitive and physiological flexibility, this intervention 
could facilitate clinical change indirectly through increased flexibility in these domains. In 
terms of cognitive flexibility such change could reduce the perseverative processing of threats 
and thus reduce the impacts of events on patients with PD. This could in turn lead to reduced 
distress and more cognitive resources available for daily functioning and reappraisal of 
situations and stimuli. PE could thus act indirectly on the level of anxiety and symptoms by 
breaking the viscous perpetuating circle of this disorder. Accordingly, PE, regardless of other 
anxiolytic effects, could possibly act on the anxious individual through increased 
psychophysiological changeability and adaptability. This would be expected to result in 
decreased anxiety in its own right. However, it would also seem plausible that the amount of 
clinical change following treatment with PE would be partly determined by what other 
therapeutic steps made by the individual. In the current treatment study we found PE to lead 
to large reduction in symptoms, and in particular on appraisal of bodily sensations and 
agoraphobic cognitions (i.e. fear of fear). The differences between the two treatments were 
largest in terms of changes in overt behaviour, as measured by mobility in everyday 
situations. This indicates that while cognitions relating to panic and anxiety were reduced 
following PE, this did not necessarily lead to increased exposure to such situations to the 
66
extent seen following CBT where this is targeted directly. According to this line of reasoning, 
PE could be an important adjunct to other interventions for PD and anxiety, and pilot studies 
have indicated that such a combination can be acceptable to patients (Cromarty, Robinson, 
Callcott, & Freeston, 2004; Merom et al., 2008). 
5.3 Methodological Issues 
5.3.1 Validity 
The question whether the current findings can be generalised to the global population is 
paramount when interpreting the findings of a given study. The three studies reported upon in 
the current thesis have all investigated the same sample; the subjects recruited for 
participation in the RCT.
As the current study was implemented within a district psychiatric centre (DPS), it was 
desirable to be able to treat patients with PD that were naturally referred to the centre. 
Furthermore, this was the first comparison of PE against an evidence-based intervention, thus 
if PE had proven to be a recommendable treatment option, it was important that it was valid 
for patients referred for treatment within secondary care for psychiatric disorders. As 
described in section 3.2.1, the majority of patients were eventually recruited via the local 
press. This could be a threat to the generalisability of the current results to the populations 
found in district psychiatric centres. However, participants in the current sample had on 
average suffered from PD for a mean of 10 years, and this is comparable to what has been 
found in clinical populations in other district psychiatric centres in the area (Nordgreen, Haug, 
Öst, Heiervang, & Havik, 2011). It should be noted that the duration of illness in the current 
study is substantially longer than what has been reported for the samples in the studies by 
Broocks et al. (1998) and Clark et al. (1994; 1999), where participants had suffered from PD 
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for approximately three years. This is not surprising, as all three studies above recruited a 
more selected sample than what was the case for the present study. Most notably, participants 
in those studies were required to report panic attacks within the last two weeks before 
inclusion. We chose to omit this criterion with reference to clinical validity as frequency of 
panic attacks is known to vary widely, and patients with PD can be free from panic attacks for 
extended periods (APA, 2000). Longer duration of illness has been associated with poorer 
treatment response (Chavira et al., 2009). This is perhaps not surprising, as a more chronic 
sample would be less likely to show spontaneous recovery, even though spontaneous recovery 
is known to be relative infrequent in PD (Wittchen & Essau, 1993). Considering this, and the 
notion that the current study included a less selected sample, it should come as no surprise 
that the current study reported somewhat smaller effects for both interventions, and lower 
treatment response to CBT compared to the studies by Broocks et al. (1998) and Clark et al. 
(1994; 1999). However, based on what has been said above, it is possible that the current 
findings represent a more valid estimate of the size of effects that can be expected when 
treating patients with PD with PE or CBT within this clinical setting. 
 However, other characteristics of the current sample could influence the interpretation 
of the findings in this thesis. The current sample showed a clear female preponderance. PD is 
known to be at least twice as prevalent in females, whereas more than 80% of the participants 
in the current sample were female. The number of males was too low for allowing 
investigation of gender differences in treatment effect, thus it is not known whether the 
current results can be applied with more certainty to females than males. This means that the 
results reported in the current thesis should be treated with caution regarding the 
generalisation to the community. This is particularly true regarding the results including 
HRV, as this measure is known to show different values for males and females as well as 
across age (Agelink et al., 2001). The relationship between HRV and Panic duration was 
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controlled for the influence of age, but a more fine grained analysis of sub-groups was not 
possible with the current sample size. Therefore, the findings related to HRV are primarily 
applicable to females in the same age as those in the current study. 
5.3.2 Power 
Due to a lack of previous studies that had compared PE to psychotherapy, the power-analysis 
that proceeded inclusion and recruitment to the RCT in the current thesis was based on 
previous findings from single studies that had either compared CBT to a tricyclic 
antidepressant, (imipramine; Clark et al., 1994) or PE to a comparable1 tricyclic 
antidepressant (clomipramine; Broocks et al., 1998). Though these two studies were 
comparable in many respects, they did not employ directly comparable outcome measures. 
However, they both reported results on composite measures that comprised assessments of 
avoidance, fear of fear as well as ratings of panic severity and frequency. Thus, the current 
power-analysis was based on the relative differences between the two active treatments and 
the control condition at post-treatment. Broocks el al. (1998) found no significant differences 
between the two active treatments, whereas there were large differences between the CBT and 
imipramine following treatment in the study by Clark et al. (1994). We therefore expected a 
difference between the two treatments at post-treatment of at least 1.0, and with reference to 
the studies by Clark et al. (1994; 1999) this effect was expected to endure following CBT, 
whereas for PE it was possible that this effect would decay over time (Martinsen, Sandvik, et 
al., 1989). From a conservative perspective, we set the expected effect to be 0.9. We used and 
allocation ratio of 1, alpha level of .05, a power of .80 (one-tailed), and conducted the analysis 
with the G*Power software (Faul, Erdfelder, Lang, & Buchner, 2007). This indicated that a 
sample of 16 participants in each group would be sufficient.
                                                
1 It should be noted that these two antidepressants have been shown to yield somewhat different effects for PD 
(Modigh, Westberg, & Eriksson, 1992). 
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However, as described above, we included a more chronic sample than what had been 
investigated in the studies referred to above. We also had fewer exclusion criteria for 
participation than in those studies, and this could have resulted in a less homogenous sample. 
Such increased variability within the sample could dilute treatment effects and demand a 
larger sample to detect possible differences between the treatments. Also, as described above, 
the power analysis was based on composite measures. Not all measures are equally sensitive 
to change, thus it is possible that some non-significant findings could have become significant 
with a larger sample. However, as an RCT compares two treatments in which one is expected 
to yield better effects than the other, overshooting the estimated sample required is not 
unproblematic from an ethical perspective. 
The issue of power is also relevant regarding the two baseline studies. From what has 
been described above, it is evident that the sample size was determined based on the treatment 
effects expected in the RCT. Both of the baseline studies reported large effect sizes that were 
in line with expectations, though not all of these were significant. This was most notable for 
the relationships between attentional shifting and the psychophysiological variables, that were 
all large, but not significant. Equivalently, the relationships between sleep quality and 
cognitive inhibition were both consistent and of large magnitude. They were however not all 
significant, despite these large effect sizes. 
5.3.3 Other methodological issues 
Apart from the methodological issues described regarding power and validity, other 
methodological challenges, obvious with the bias of hindsight, have become apparent. These 
are described below. 
As we compared PE to another intervention in the RCT, it would have been useful to 
be able to document an improvement in physical condition following the treatment period. 
We opted for the sub-maximal assessment in the 6MWT. However, a more reliable 
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manipulation check such as assessment of VO2max could have been preferred. Assessment of 
VO2max is the gold standard for testing of physical capacity. Still, when the study was planned, 
previous studies and recommendations indicated that improved physical fitness was not 
necessary for anxiety reduction (Martinsen, Hoffart, et al., 1989; Meyer & Broocks, 2000). 
Furthermore, assessment of maximal capacity requires an intensive bout of PE. Based on the 
findings that an acute bout of PE can be panicogenic for patients with PD (Esquivel et al., 
2008; Ströhle et al., 2009), we were worried that such testing could amount to an intervention 
in its own right. The current PE-treatment was intended to be implementable within secondary 
mental health care, where assessment of VO2max would not be readily available. Performing 
this assessment could thus reduce the validity of possible findings on PE for these settings. 
There are also submaximal methods for estimating VO2 capacity, but these also require 
physical exercise of a fairly high intensity, something that would be aversive to a substantial 
proportion of patients prior to treatment. We therefore decided to use a less demanding 
submaximal assessment, where the participants could choose the physical output that they 
were comfortable with, while the treatment was conducted according to a rigorous manual. 
Also, in the assessment of treatment effects in the RCT, ratings of panic severity (i.e. 
panic-related distress and disability) and frequency of panic attacks were combined in one 
MANOVA. However, scores and changes on these measures are not necessarily highly 
related (Chambless, 1985; Craske & Barlow, 1988), and combining these measures in one 
analysis as was done here, could have diluted possible effects. 
 Sleep impairment was assessed using a self-report measure. Insomnia is a subjective 
disorder, and in the current study the assessment of subjectively rated sleep impairment within 
one sample was used to the advantage of investigating the current research questions. 
However, the role of cognitive inhibition should also be investigated using objective measures 
of sleep quality. Although sleep problems are known to be prevalent in patients with PD, it is 
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possible that these patients’ anxiety lead to overestimations of experienced sleep problems. A 
recent study indicated that patients with PD differ on subjective and objective measures of 
sleep following psychopharmacological treatment (Todder & Baune, 2010). In that study, 
actigraphy was used as the objective measure of sleep, and even though the validity of this 
measure has been questioned (Sivertsen et al., 2006), the study by Todder and Baune (2010) 
underlines the need for further research to clarify this.
5.4 Ethical Considerations 
There is always an ethical challenge when assigning participants to different treatment options 
in research. This is related to the core of this research, that one treatment is expected to be 
favourable over the other. In the study in the current thesis we expected the established 
treatment to yield better effects, but we wanted to assess the long-term and clinically 
significant effects of PE. This was important, as the recommended treatment for PD is 
currently scarcely available to those who need this treatment, while PE has been suggested as 
treatment for PD (Asmundson et al., in press; Otto et al., 2007; Smits et al., 2007). This did 
however mean that approximately half of the participants in the current study received the 
treatment that had a less certain clinical efficacy; PE.
 The load related to assessments for those participating in treatment studies is also an 
important ethical consideration. PD is a disorder that is regularly assessed by a range of 
measures in treatment studies. The reason for this is that one is interested in detecting change 
both at a behavioural (i.e. mobility and avoidance) and cognitive level (i.e. fear of fear and 
sensitivity to bodily sensations). It is also important to know the frequency and severity of 
panic attacks. In addition, validity measures of general anxiety, depression and quality of life 
are generally recommended to determine whether changes relating to PD have had an impact 
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on other life domains. In the studies in the current thesis, we also wanted to investigate 
psychophysiology in these patients, and this obviously increased the load and time spent on 
assessments for the participants. This toll must always be weighed against the possible 
scientific value of the research questions. One obvious implication from this is that all data 
that are collected should be used to further scientific knowledge on PD and consequences of 
this disorder. 
5.5 Conclusions and Recommendations 
PE on its own appears to yield large and enduring reductions in anxiety and symptoms of 
panic disorder, albeit considerable smaller and less consistent than CBT. Importantly, PE did 
not lead to clinically significant change as assessed according to recommendations. 
Furthermore, we found measures of key executive functions to be related to vagally mediated 
HRV in patients with PD. This supports theoretical models linking cardiac regulation to 
activity in the prefrontal cortex, and demonstrates that this relationship is also present in 
anxious subjects, specifically in PD, the anxiety disorder most consistently linked do 
decreased vagally mediated HRV. Furthermore, results indicated that severity and duration of 
PD affects, or is affected by these same measures of cognitive and physiological flexibility. 
This is important, as PD is associated with increased mortality, supposedly mediated by the 
characteristically decreased HRV in these patients. Cognitive and possibly physiological 
flexibility were also found to be related to key measures of sleep impairment in patients with 
PD. This is in line with theoretical developments on insomnia. These findings first and 
foremost indicate the need for further research on the role of these measures as risk factors for 
clinical deterioration and development of co-morbidity in PD. PD and panic is associated with 
a more malign clinical course, and the findings that cognitive and physiological flexibility is 
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associated with sleep impairment and symptoms of insomnia is noteworthy. PD is the most 
frequent co-morbidity to depression (Roy-Byrne et al., 2000), a disorder that has also been 
associated with impaired cognitive inhibition, also following remission (Årdal & Hammar, 
2011; Biringer et al., 2007; Hammar et al., 2010). Impaired executive functioning and reduced 
physiological flexibility has been suggested to constitute risk factors for development of 
anxiety and impairment associated with anxiety. If these factors are also related to the 
development of co-morbidity in PD, they should be considered targets for intervention, or be 
considered as outcome measures following treatment for PD. More should also be known 
regarding to what extent change on these psychophysiological variables is related to clinical 
change or lack thereof during treatment for anxiety. 
PE can modulate measures of both these psychophysiological domains, and in the current 
thesis we have found PE to produce substantial and lasting effects on measures of PD and 
anxiety, although clinical changes following from PE appear not to be large enough to 
constitute clinical recovery. A natural suggestion following from these findings is that it 
should be assessed how the effects of PE can be harnessed and used in conjunction with an 
established treatment for anxiety such as CBT. This may provide an even more effective and 
robust treatment for PD, and especially if PE for PD also works through other mechanisms 
than only exposure to bodily sensations. However, from a societal perspective, combining 
CBT and PE as treatment for PD would not necessarily provide increased availability of 
treatment, as it often would require the presence of a therapist. Thus, the combination of PE 
and self-help or guided self-help would seem a more viable combination to provide additional 
available, effective and cost-effective treatment for PD. The feasibility and efficacy of such a 
combination could yield important insights, and possibly an improved intervention for 
patients suffering from this disorder. 
74
6.0 References 
Agelink, M., Malessa, R., Baumann, B., Majewski, T., Akila, F., Zeit, T., & Ziegler, D. 
(2001). Standardized tests of heart rate variability: normal ranges obtained from 309 
healthy humans, and effects of age, gender, and heart rate. Clinical Autonomic 
Research, 11, 99-108. 
Ahern, G. L., Sollers, J. J., Lane, R. D., Labiner, D. M., Herring, A. M., Weinand, M. E., . . . 
Thayer, J. F. (2001). Heart rate and heart rate variability changes in the intracarotid 
sodium amobarbital test. Epilepsia, 42, 912-921. 
Alvarenga, M. E., Richards, J. C., Lambert, G., & Esler, M. D. (2006). Psychophysiological 
mechanisms in panic disorder: a correlative analysis of noradrenaline spillover, 
neuronal noradrenaline reuptake, power spectral analysis of heart rate variability, and 
psychological variables. Psychosomatic Medicine, 68, 8-16. 
Alvarez, J., & Emory, E. (2006). Executive function and the frontal lobes: a meta-analytic 
review. Neuropsychology Review, 16, 17-42. 
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental 
disorders (4th ed., text revision). Washington, DC: American Psychiatric Association. 
Andrews, G., Creamer, M., Crino, R., Hunt, C., & Lampe, L. (2003). The treatment of anxiety 
disorders: Clinician guides and patient manuals. Cambridge: Cambridge University 
Press.
Appelhans, B. M., & Luecken, L. J. (2006). Heart rate variability as an index of regulated 
emotional responding. Review of General Psychology, 10, 229-240. 
Asmundson, G. J. G., Fetzner, M. G., DeBoer, L. B., Powers, M. B., Otto, M. W., & Smits, J. 
A. J. (in press). Let's get physical: a contemporary review of the anxiolytic effects of 
exercise for anxiety and its disorders. Depression and Anxiety. doi:10.1002/da.22043 
Baillie, A. J., & Rapee, R. M. (2004). Predicting who benefits from psychoeducation and self 
help for panic attacks. Behaviour Research and Therapy, 42, 513-527. 
Barbas, H., Saha, S., Rempel-Clower, N., & Ghashghaei, T. (2003). Serial pathways from 
primate prefrontal cortex to autonomic areas may influence emotional expression. 
BMC Neuroscience, 4, 25. 
Barber, J. P., Liese, B. S., & Abrams, M. J. (2003). Development of the Cognitive Therapy 
Adherence and Competence Scale. Psychotherapy Research, 13, 205-221. 
Barlow, D. H. (2002). Anxiety and its disorders: The nature and treatment of anxiety and 
panic (2nd ed.). New York: Guilford Press. 
Bastien, C. (2011). Insomnia: Neurophysiological and neuropsychological approaches. 
Neuropsychology Review, 21, 22-40. 
Bastien, C. H., St-Jean, G., Morin, C. M., Turcotte, I., & Carrier, J. (2008). Chronic 
psychophysiological insomnia: hyperarousal and/or inhibition deficits? An ERPs 
investigation. Sleep, 31, 887-898. 
Beck, A. T., & Steer, R. A. (1993). Beck Anxiety Inventory manual. San Antonio, TX: The 
Psychological Corporation. 
Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Beck Depression Inventory-II manual. San 
Antonio, TX: The Psychological Corporation. 
Benitez, A., & Gunstad, J. (2012). Poor sleep quality diminishes cognitive functioning 
independent of depression and anxiety in healthy young adults. The Clinical 
Neuropsychologist, 26, 214-223. 
75
Bijl, R. V., Ravelli, A., & van Zessen, G. (1998). Prevalence of psychiatric disorder in the 
general population: results of the Netherlands Mental Health Survey and Incidence 
Study (NEMESIS). Social Psychiatry and Psychiatric Epidemiology, 33, 587-595. 
Biringer, E., Mykletun, A., Sundet, K., Kroken, R., Stordal, K. I., & Lund, A. (2007). A 
longitudinal analysis of neurocognitive function in unipolar depression. Journal of 
Clinical and Experimental Neuropsychology, 29, 879-891. 
Bonnet, M., & Arand, D. (1998). Heart rate variability in insomniacs and matched normal 
sleepers. Psychosomatic Medicine, 60, 610-615. 
Borbély, A. A. (1982). A two process model of sleep regulation. Human Neurobiology, 1,
195-204.
Boutcher, S. H., & Landers, D. M. (1988). The effects of vigorous exercise on anxiety, heart 
rate, and alpha activity of runners and nonrunners. Psychophysiology, 25, 696-702. 
Boutcher, Y. N., & Boutcher, S. H. (2006). Cardiovascular response to Stroop: Effect of 
verbal response and task difficulty. Biological Psychology, 73, 235-241. 
Broman-Fulks, J. J., Berman, M. E., Rabian, B. A., & Webster, M. J. (2004). Effects of 
aerobic exercise on anxiety sensitivity. Behaviour Research and Therapy, 42, 125-
136.
Broman-Fulks, J. J., & Storey, K. M. (2008). Evaluation of a brief aerobic exercise 
intervention for high anxiety sensitivity. Anxiety Stress and Coping, 21, 117-128. 
Broocks, A., Bandelow, B., Pekrun, G., George, A., Meyer, T., Bartmann, U., . . . Ruther, E. 
(1998). Comparison of aerobic exercise, clomipramine, and placebo in the treatment 
of panic disorder. American Journal of Psychiatry, 155, 603-609. 
Brosschot, J. F., Gerin, W., & Thayer, J. F. (2006). The perseverative cognition hypothesis: A 
review of worry, prolonged stress-related physiological activation, and health. Journal
of Psychosomatic Research, 60, 113-124. 
Buckworth, J., & Dishman, R. K. (2002). Exercise psychology. Champaign: Human Kinetics 
Publishers.
Buysse, D. J., Ancoli-lsrael, S., Edinger, J. D., Lichstein, K. L., & Morin, C. M. (2006). 
Recommendations for a standard research assessment of insomnia. Sleep, 29, 1155-
1173.
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The 
Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. 
Psychiatry Research, 28, 193-213. 
Carlbring, P., Bohman, S., Brunt, S., Buhrman, M., Westling, B., Ekselius, L., & Andersson, 
G. (2006). Remote treatment of panic disorder: a randomized trial of internet-based 
cognitive behavior therapy supplemented with telephone calls. American Journal of 
Psychiatry, 163, 2119-2125. 
Chambless, D. L. (1985). The relationship of severity of agoraphobia to associated 
psychopathology. Behaviour Research and Therapy, 23, 305-310. 
Chambless, D. L., Caputo, G. C., Bright, P., & Gallagher, R. (1984). Assessment of fear of 
fear in agoraphobics: The Body Sensations Questionnaire and the Agoraphobic 
Cognitions Questionnaire. Journal of Consulting and Clinical Psychology, 52, 1090-
1097.
Chambless, D. L., Caputo, G. C., Jasin, S. E., Gracely, E. J., & Williams, C. (1985). The 
Mobility Inventory for Agoraphobia. Behaviour Research and Therapy, 23, 35-44. 
Chang, Y. K., & Etnier, J. L. (2009). Effects of an acute bout of localized resistance exercise 
on cognitive performance in middle-aged adults: A randomized controlled trial study. 
Psychology of Sport and Exercise, 10, 19-24. 
Chavira, D. A., Stein, M. B., Golinelli, D., Sherbourne, C. D., Craske, M. G., Sullivan, G., . . . 
Roy-Byrne, P. P. (2009). Predictors of clinical improvement in a randomized 
76
effectiveness trial for primary care patients with panic disorder. The Journal of 
Nervous and Mental Disease, 197, 715-721. 
Clark, D. M. (1986). A cognitive approach to panic. Behaviour Research and Therapy, 24,
461-470.
Clark, D. M., Salkovskis, P. M., Hackmann, A., Middleton, H., Anastasiades, P., & Gelder, 
M. (1994). A comparison of cognitive therapy, applied relaxation and imipramine in 
the treatment of panic disorder. The British Journal of Psychiatry, 164, 759-769. 
Clark, D. M., Salkovskis, P. M., Hackmann, A., Wells, A., Ludgate, J., & Gelder, M. (1999). 
Brief cognitive therapy for panic disorder: A randomized controlled trial. Journal of 
Consulting and Clinical Psychology, 67, 583-589. 
Coats, A. J., Adamopoulos, S., Radaelli, A., McCance, A., Meyer, T. E., Bernardi, L., . . . 
Forfar, C. (1992). Controlled trial of physical training in chronic heart failure. 
Exercise performance, hemodynamics, ventilation, and autonomic function. 
Circulation, 85, 2119-2131. 
Cohen, H., Benjamin, J., Geva, A. B., Matar, M. A., Kaplan, Z., & Kotler, M. (2000). 
Autonomic dysregulation in panic disorder and in post-traumatic stress disorder: 
application of power spectrum analysis of heart rate variability at rest and in response 
to recollection of trauma or panic attacks. Psychiatry Research, 96, 1-13. 
Cohen, J. (1988). Statistical power analysis for the behavioral sciences. Hillsdale, NJ: 
Lawrence Erlbaum. 
Colcombe, S., & Kramer, A. F. (2003). Fitness effects on the cognitive function of older 
adults: a meta-analytic study. Psychological Science, 14, 125-130. 
Crapo, R. O., Casaburi, R., Coates, A. L., Enright, P. L., MacIntyre, N. R., McKay, R. T., . . . 
Comm, A. T. S. (2002). ATS statement: Guidelines for the six-minute walk test. 
American Journal of Respiratory and Critical Care Medicine, 166, 111-117. 
Craske, M. G., & Barlow, D. H. (1988). A review of the relationship between panic and 
avoidance. Clinical Psychology Review, 8, 667-685. 
Crestani, F., Lorez, M., Baer, K., Essrich, C., Benke, D., Laurent, J. P., . . . Mohler, H. (1999). 
Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for 
threat cues. Nature Neuroscience, 2, 833-839. 
Cromarty, P., Robinson, G., Callcott, P., & Freeston, M. (2004). Cognitive therapy and 
exercise for panic and agoraphobia in primary care: pilot study and service 
development. Behavioural and Cognitive Psychotherapy, 32, 371-374. 
Dammen, T., Arnesen, H., Ekeberg, Ø., Husebye, T., & Friis, S. (1999). Panic disorder in 
chest pain patients referred for cardiological outpatient investigation. Journal of 
Internal Medicine, 245, 497-507. 
de Geus, E. J. C., Willemsen, G. H. M., Klaver, C. H. A. M., & van Doornen, L. J. P. (1995). 
Ambulatory measurement of respiratory sinus arrhythmia and respiration rate. 
Biological Psychology, 41, 205-227. 
De Moor, M. H. M., Beem, A. L., Stubbe, J. H., Boomsma, D. I., & De Geus, E. J. C. (2006). 
Regular exercise, anxiety, depression and personality: A population-based study. 
Preventive Medicine, 42, 273-279. 
Delaney, J., & Brodie, D. (2000). Effects of short-term psychological stress on the time and 
frequency domains of heart-rate variability. Perceptual and Motor Skills, 91, 515-524. 
Delis, D. D., Kaplan, E., & Kramer, J. H. (2001). Delis-Kaplan Executive Function System 
(D-KEFS). Norwegian version. Stockholm: Pearson Assessment. 
Dishman, R. K., Dunn, A. L., Youngstedt, S. D., Davis, J. M., Burgess, M. L., Wilson, S. P., 
& Wilso, M. A. (1996). Increased open field locomotion and decreased striatal 
GABAA binding after activity wheel running. Physiology & Behavior, 60, 699-705. 
77
Dupont, H., Mollard, E., & Cottraux, J. (2000). Visuo-spatial attention processes in panic 
disorder with agoraphobia: a pilot study using a visual target discrimination task. 
European Psychiatry, 15, 254-260. 
Duschek, S., Muckenthaler, M., Werner, N., & Reyes del Paso, G. A. (2009). Relationships 
between features of autonomic cardiovascular control and cognitive performance. 
Biological Psychology, 81, 110-117. 
Elliot, A. J., Payen, V., Brisswalter, J., Cury, F., & Thayer, J. F. (2011). A subtle threat cue, 
heart rate variability, and cognitive performance. Psychophysiology, 48, 1340-1345. 
Enright, P. L. (2003). The six-minute walk test. Respiratory Care, 48, 783-785. 
Espie, C. A. (2002). Insomnia: Conceptual issues in the development, persistence, and 
treatment of sleep disorder in adults. Annual Review of Psychology, 53, 215-243. 
Esquivel, G., Diaz-Galvis, J., Schruers, K., Berlanga, C., Lara-Munoz, C., & Griez, E. (2008). 
Acute exercise reduces the effects of a 35% CO2 challenge in patients with panic 
disorder. Journal of Affective Disorders, 107, 217-220. 
Esquivel, G., Schruers, K., Kuipers, H., & Griez, E. (2002). The effects of acute exercise and 
high lactate levels on 35% CO2 challenge in healthy volunteers. Acta Psychiatrica 
Scandinavica, 106, 394-397. 
Eysenck, M. W., Derakshan, N., Santos, R., & Calvo, M. G. (2007). Anxiety and cognitive 
performance: Attentional control theory. Emotion, 7, 336-353. 
Faul, F., Erdfelder, E., Lang, A. G., & Buchner, A. (2007). G*Power 3: a flexible statistical 
power analysis program for the social, behavioral, and biomedical sciences. Behavior
Research Methods, 39, 175-191. 
First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (1995). Structured Clinical 
Interview for DSM-IV Axis I Disorders-Patient edition (SCID-I/P, Version 2.0). 
Biometric Research Department, New York State Psychiatric Institute: New York.
First, M. B., Spitzer, R. L., Gibbon, M., Williams, J. B. W., & Benjamin, L. (1994). 
Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II, 
Version 2.0). Biometrics Research Department, New York State Psychiatric Institute: 
New York.
Friedman, B. H. (2007). An autonomic flexibility-neurovisceral integration model of anxiety 
and cardiac vagal tone. Biological Psychology, 74, 185-199. 
Frisch, M. B., Cornell, J., Villanueva, M., & Retzlaff, P. J. (1992). Clinical validation of the 
Quality of Life Inventory: A measure of life satisfaction for use in treatment planning 
and outcome assessment. Psychological Assessment, 4, 92-101. 
Garakani, A., Martinez, J. M., Aaronson, C. J., Voustianiouk, A., Kaufmann, H., & Gorman, 
J. M. (2009). Effect of medication and psychotherapy on heart rate variability in panic 
disorder. Depression and Anxiety, 26, 251-258. 
Goldman-Rakic, P. (1998). The prefrontal landscape: implications of functional architecture 
for understanding human mentation and the central executive. In A. C. Roberts, T. W. 
Robbins & L. Weiskrantz (Eds.), The prefrontal cortex: Executive and cogntive 
functions (pp. 87-102). Oxford: Oxford University Press. 
Gomez-Caminero, A., Blumentals, W. A., Russo, L. J., Brown, R. R., & Castilla-Puentes, R. 
(2005). Does panic disorder increase the risk of coronary heart disease? A cohort 
study of a national managed care database. Psychosomatic Medicine, 67, 688-691. 
Goodwin, R. D. (2003). Association between physical activity and mental disorders among 
adults in the United States. Preventive Medicine, 36, 698-703. 
Goodwin, R. D., Lieb, R., Hoefler, M., Pfister, H., Bittner, A., Beesdo, K., & Wittchen, H. U. 
(2004). Panic attack as a risk factor for severe psychopathology. American Journal of 
Psychiatry, 161, 2207-2214. 
78
Habib, G. (1999). Reappraisal of heart rate as a risk factor in the general population. 
European Heart Journal Supplements, 1 (H), H2-H10. 
Hammar, Å., Sørensen, L., Årdal, G., Ødegaard, K. J., Kroken, R., Roness, A., & Lund, A. 
(2010). Enduring cognitive dysfunction in unipolar major depression: A test–retest 
study using the Stroop paradigm. Scandinavian Journal of Psychology, 51, 304-308. 
Hansen, A. L., Johnsen, B. H., Sollers, J. J., Stenvik, K., & Thayer, J. F. (2004). Heart rate 
variability and its relation to prefrontal cognitive function: the effects of training and 
detraining. European Journal of Applied Physiology, 93, 263-272. 
Hansen, A. L., Johnsen, B. H., & Thayer, J. F. (2003). Vagal influence on working memory 
and attention. International Journal of Psychophysiology, 48, 263-274. 
Harvey, A. G. (2002). A cognitive model of insomnia. Behaviour Research and Therapy, 40,
869-893.
Harvey, A. G., & Spielman, A. J. (2011). Insomnia: Diagnosis, assessment, and outcomes. In 
M. H. Kryger, T. Roth & W. C. Dement (Eds.), Principles and practice of sleep 
medicine (pp. 838-850). Missouri: Elsevier. 
Harvey, S. B., Hotopf, M., Overland, S., & Mykletun, A. (2010). Physical activity and 
common mental disorders. The British Journal of Psychiatry, 197, 357-364. 
Haskell, W. L., Lee, I. M., Pate, R. R., Powell, K. E., Blair, S. N., Franklin, B. A., . . . 
Bauman, A. (2007). Physical activity and public health: updated recommendation for 
adults from the American College of Sports Medicine and the American Heart 
Association. Medicine and Science in Sports and Exercise, 39, 1423-1434. 
Haug, T., Nordgreen, T., Öst, L. G., & Havik, O. E. (2012). Self-help treatment of anxiety 
disorders: A meta-analysis and meta-regression of effects and potential moderators. 
Clinical Psychology Review, 32, 425-445. 
Heaton, R., PAR Staff, & Goldin, J. (2003). WCST: CV4 Wisconsin Card Sorting Test: 
Computer Version 4 research edition user’s manual. Lutz, FL: Psychological 
Assessment Resources Inc. 
Herring, M. P., Jacob, M. L., Suveg, C., Dishman, R. K., & O’Connor, P. J. (2012). 
Feasibility of exercise training for the short-term treatment of generalized anxiety 
disorder: a randomized controlled trial. Psychotherapy and Psychosomatics, 81, 21-28. 
Howell, D. C. (2012). Statistical methods for psychology. Belmont: Wadsworth Pub Co. 
Jacobson, N. S., & Truax, P. (1991). Clinical significance: A statistical approach to defining 
meaningful change in psychotherapy research. Journal of Consulting and Clinical 
Psychology, 59, 12-19. 
Johnsen, B. H., Thayer, J. F., Laberg, J. C., Wormnes, B., Raadal, M., Skaret, E., . . . Berg, E. 
(2003). Attentional and physiological characteristics of patients with dental anxiety. 
Journal of Anxiety Disorders, 17, 75-87. 
Jonsbu, E., Dammen, T., Morken, G., Lied, A., Vik-Mo, H., & Martinsen, E. W. (2009). 
Cardiac and psychiatric diagnoses among patients referred for chest pain and 
palpitations. Scandinavian Cardiovascular Journal, 43, 256-259. 
Jouven, X., Zureik, M., Desnos, M., Guérot, C., & Ducimetière, P. (2001). Resting heart rate 
as a predictive risk factor for sudden death in middle-aged men. Cardiovascular
Research, 50, 373-378. 
Kashdan, T. B., & Rottenberg, J. (2010). Psychological flexibility as a fundamental aspect of 
health. Clinical Psychology Review, 30, 865-878. 
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005). 
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the 
National Comorbidity Survey Replication. Archives of General Psychiatry, 62, 593-
602.
79
Kessler, R. C., Chiu, W. T., Jin, R., Ruscio, A. M., Shear, K., & Walters, E. E. (2006). The 
epidemiology of panic attacks, panic disorder, and agoraphobia in the national 
comorbidity survey replication. Archives of General Psychiatry, 63, 415-424. 
Kessler, R. C., McGonagle, K. A., Zhao, S., Nelson, C. B., Hughes, M., Eshleman, S., . . . 
Kendler, K. S. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric 
disorders in the United States: results from the National Comorbidity Survey. Archives
of General Psychiatry, 51, 8-19. 
Klein, E., Cnaani, E., Harel, T., Braun, S., & Ben-Haim, S. A. (1995). Altered heart rate 
variability in panic disorder patients. Biological Psychiatry, 37, 18-24. 
Lane, R. D., McRae, K., Reiman, E. M., Chen, K., Ahern, G. L., & Thayer, J. F. (2009). 
Neural correlates of heart rate variability during emotion. Neuroimage, 44, 213-222. 
Lautenbacher, S., Spernal, J., & Krieg, J.-C. (2002). Divided and selective attention in panic 
disorder. European Archives of Psychiatry and Clinical Neuroscience, 252, 210-213. 
Lawlor, D. A., & Hopker, S. W. (2001). The effectiveness of exercise as an intervention in the 
management of depression: Systematic review and meta-regression analysis of 
randomised controlled trials. British Medical Journal, 322, 763-767. 
Levy, M. N. (2006). Autonomic interactions in cardiac control. Annals of the New York 
Academy of Sciences, 601, 209-221. 
Levy, W. C., Cerqueira, M. D., Harp, G. D., Johannessen, K. A., Abrass, I. B., Schwartz, R. 
S., & Stratton, J. R. (1998). Effect of endurance exercise training on heart rate 
variability at rest in healthy young and older men. The American Journal of 
Cardiology, 82, 1236-1241. 
Lichstein, K. L., Taylor, D. J., McCrae, C. S., & Ruiter, M. E. (2011). Models of insomnia. In 
M. H. Kryger, T. Roth & W. C. Dement (Eds.), Principles and practice of sleep 
medicine (pp. 827-838). Missouri: Elsevier. 
Lippa, S. M., & Davis, R. N. (2010). Inhibition/switching is not necessarily harder than 
inhibition: An analysis of the D-KEFS color-word interference test. Archives of 
Clinical Neuropsychology, 25, 146-152. 
Long, B. C., & van Stavel, R. (1995). Effects of exercise training on anxiety: A meta-analysis. 
Journal of Applied Sport Psychology, 7, 167 - 189. 
Malik, M., Bigger, J., Camm, A., Kleiger, R., Malliani, A., & Moss, A. (1996). Guidelines: 
Heart rate variability, standards of measurement, physiological interpretation, and 
clinical use. European Heart Journal, 17, 354-381. 
Martinsen, E. W., Hoffart, A., & Solberg, O. Y. (1989). Aerobic and non-aerobic forms of 
exercise in the treatment of anxiety disorders. Stress Medicine, 5, 115-120. 
Martinsen, E. W., Sandvik, L., & Kolbjørnsrud, O. B. (1989). Aerobic exercise in the 
treatment of nonpsychotic mental disorders: An exploratory study. Nordic Journal of 
Psychiatry, 43, 521-529. 
Mathewson, K. J., Jetha, M. K., Drmic, I. E., Bryson, S. E., Goldberg, J. O., Hall, G. B., . . . 
Schmidt, L. A. (2010). Autonomic predictors of Stroop performance in young and 
middle-aged adults. International Journal of Psychophysiology, 76, 123-129. 
McHugh, R. K., Otto, M. W., Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. 
(2007). Cost-efficacy of individual and combined treatments for panic disorder. The
Journal of Clinical Psychiatry, 68, 1038-1044. 
McManus, F., Grey, N., & Shafran, R. (2008). Cognitive therapy for anxiety disorders: 
Current status and future challenges. Behavioural and Cognitive Psychotherapy, 36,
695-704.
Mellman, T. A., & Uhde, T. W. (1989). Sleep panic attacks: New clinical findings and 
theoretical implications. The American Journal of Psychiatry, 146, 1204-1207. 
80
Melzig, C. A., Weike, A. I., Hamm, A. O., & Thayer, J. F. (2009). Individual differences in 
fear-potentiated startle as a function of resting heart rate variability: Implications for 
panic disorder. International Journal of Psychophysiology, 71, 109-117. 
Merom, D., Phongsavan, P., Wagner, R., Chey, T., Marnane, C., Steel, Z., . . . Bauman, A. 
(2008). Promoting walking as an adjunct intervention to group cognitive behavioral 
therapy for anxiety disorders--A pilot group randomized trial. Journal of Anxiety 
Disorders, 22, 959-968. 
Meyer, T., & Broocks, A. (2000). Therapeutic impact of exercise on psychiatric diseases: 
guidelines for exercise testing and prescription. Sports Medicine, 30, 269-279. 
Middleton, H. C., Ashby, M., & Robbins, T. W. (1994). Reduced plasma noradrenaline and 
abnormal heart rate variability in resting panic disorder patients. Biological
Psychiatry, 36, 847-849. 
Miyake, A., Friedman, N. P., Emerson, M. J., Witzki, A. H., Howerter, A., & Wager, T. D. 
(2000). The unity and diversity of executive functions and their contributions to 
complex “frontal lobe” tasks: a latent variable analysis. Cognitive Psychology, 41, 49-
100.
Modigh, K., Westberg, P., & Eriksson, E. (1992). Superiority of clomipramine over 
imipramine in the treatment of panic disorder: A placebo-controlled trial. Journal of 
Clinical Psychopharmacology, 12, 251-261. 
Muhsen, K., Lipsitz, J., Garty-Sandalon, N., Gross, R., & Green, M. (2008). Correlates of 
generalized anxiety disorder: Independent of co-morbidity with depression. Social
Psychiatry and Psychiatric Epidemiology, 43, 898-904. 
National Institute for Health and Clinical Excellence. (2011). Generalised anxiety disorder 
and panic disorder (with or without agoraphobia) in adults: management in primary, 
secondary and community care. (CG113). London: National Institute for Health and 
Clinical Excellence.
Nordgreen, T., Haug, T., Öst, L. G., Heiervang, E., & Havik, O. E. (2011). Stepped care vs. 
direct CBT for social phobia and panic disorder: A randomised controlled trial. Paper 
presented at the 41st annual congress for the European Association for Behavioural 
and Cognitive Therapies, Iceland.
O'Connor, P., Raglin, J., & Martinsen, E. (2000). Physical activity, anxiety and anxiety 
disorders. International Journal of Sport Psychology, 31, 136-155. 
Okuji, Y., Matsuura, M., Kawasaki, N., Kometani, S., Shimoyama, T., Sato, M., . . . Abe, K. 
(2002). Prevalence of insomnia in various psychiatric diagnostic categories. 
Psychiatry and Clinical Neurosciences, 56, 239-240. 
Orwin, A. (1974). Treatment of a situational phobia--a case for running. British Journal of 
Psychiatry, 125, 95-98. 
Otto, M. W., Church, T. S., Craft, L. L., Greer, T. L., Smits, J. A. J., & Trivedi, M. H. (2007). 
Exercise for mood and anxiety disorders. Journal of Clinical Psychiatry, 68, 669-676. 
Overbeek, T., van Diest, R., Schruers, K., Kruizinga, F., & Griez, E. (2005). Sleep complaints 
in panic disorder patients. The Journal of Nervous and Mental Disease, 193, 488-493. 
Perlis, M., Shaw, P. J., Cano, G., & Espie, C. A. (2011). Models of insomnia. In M. H. 
Kryger, T. Roth & W. C. Dement (Eds.), Principles and practice of sleep medicine
(pp. 850-865). Missouri: Elsevier. 
Perlis, M. L., Giles, D. E., Mendelson, W. B., Bootzin, R. R., & Wyatt, J. K. (1997). 
Psychophysiological insomnia: The behavioural model and a neurocognitive 
perspective. Journal of Sleep Research, 6, 179-188. 
Petruzzello, S., Jones, A., & Tate, A. (1997). Affective responses to acute exercise: a test of 
opponent-process theory. Journal of Sports Medicine and Physical Fitness, 37, 205-
212.
81
Petruzzello, S. J., Landers, D. M., Hatfield, B. D., Kubitz, K. A., & Salazar, W. (1991). A 
meta-analysis on the anxiety-reducing effects of acute and chronic exercise. Outcomes 
and mechanisms. Sports Medicine, 11, 143-182. 
Pollock, M. L., Gaesser, G. A., Butcher, J. D., Despres, J. P., Dishman, R. K., Franklin, B. A., 
& Garber, C. E. (1998). ACSM position stand: The recommended quantity and quality 
of exercise for developing and maintaining cardiorespiratory and muscular fitness, and 
flexibility in healthy adults. Medicine & Science in Sports & Exercise, 30, 975-991. 
Pull, C. B., & Damsa, C. (2008). Pharmacotherapy of panic disorder. Neuropsychiatric
Disease and Treatment, 4, 779-796. 
Richards, J. E., & Casey, B. J. (1991). Heart rate variability during attention phases in young 
infants. Psychophysiology, 28, 43-53. 
Ridderinkhof, K. R., van den Wildenberg, W. P. M., Segalowitz, S. J., & Carter, C. S. (2004). 
Neurocognitive mechanisms of cognitive control: The role of prefrontal cortex in 
action selection, response inhibition, performance monitoring, and reward-based 
learning. Brain and Cognition, 56, 129-140. 
Rogers, P. J., Tyce, G. M., Bailey, K. R., & Bove, A. A. (1991). Exercise-induced increases in 
atrial natriuretic factor are attenuated by endurance training. Journal of the American 
College of Cardiology, 18, 1236-1241. 
Rossi, A., Daneluzzo, E., Mattei, P., Bustini, M., Casacchia, M., & Stratta, P. (1997). 
Wisconsin card sorting test and Stroop test performances in Schizophrenia: a shared 
construct. Neuroscience Letters, 226, 87-90. 
Roy-Byrne, P. P., Stang, P., Wittchen, H.-U., Ustun, B., Walters, E., & Kessler, R. C. (2000). 
Lifetime panic-depression comorbidity in the National Comorbidity Survey. The
British Journal of Psychiatry, 176, 229-235. 
Salkovskis, P. M., Clark, D. M., & Hackmann, A. (1991). Treatment of panic attacks using 
cognitive therapy without exposure or breathing retraining. Behaviour Research and 
Therapy, 29, 161-166. 
Salmon, P. (2001). Effects of physical exercise on anxiety, depression, and sensitivity to 
stress: a unifying theory. Clinical Psychology Review, 21, 33-61. 
Schmidt, N. B., Lerew, D. R., & Jackson, R. J. (1999). Prospective evaluation of anxiety 
sensitivity in the pathogenesis of panic: Replication and extension. Journal of 
Abnormal Psychology, 108, 532-537. 
Scully, D., Kremer, J., Meade, M. M., Graham, R., & Dudgeon, K. (1998). Physical exercise 
and psychological well being: a critical review. British Journal of Sports Medicine, 32,
111-120.
Sexton, H., Mære, A., & Dahl, N. H. (1989). Exercise intensity and reduction in neurotic 
symptoms - a controlled follow-up-study. Acta Psychiatrica Scandinavica, 80, 231-
235.
Shafran, R., Clark, D. M., Fairburn, C. G., Arntz, A., Barlow, D. H., Ehlers, A., . . . Wilson, 
G. T. (2009). Mind the gap: Improving the dissemination of CBT. Behaviour Research 
and Therapy, 47, 902-909. 
Shekleton, J. A., Rogers, N. L., & Rajaratnam, S. M. W. (2010). Searching for the daytime 
impairments of primary insomnia. Sleep Medicine Reviews, 14, 47-60. 
Simes, R. J. (1986). An improved Bonferroni procedure for multiple tests of significance. 
Biometrika, 73, 751-754. 
Simon, N. M., Safren, S. A., Otto, M. W., Sharma, S. G., Lanka, G. D., & Pollack, M. H. 
(2002). Longitudinal outcome with pharmacotherapy in a naturalistic study of panic 
disorder. Journal of Affective Disorders, 69, 201-208. 
82
Sivertsen, B., Omvik, S., Havik, O. E., Pallesen, S., Bjorvatn, B., Nielsen, G. H., . . . Nordhus, 
I. H. (2006). A comparison of actigraphy and polysomnography in older adults treated 
for chronic primary insomnia. Sleep, 29, 1353-1358. 
Sloan, E. P., Natarajan, M., Baker, B., Dorian, P., Mironov, D., Barr, A., . . . Shapiro, C. M. 
(1999). Nocturnal and daytime panic attacks—comparison of sleep architecture, heart 
rate variability, and response to sodium lactate challenge. Biological Psychiatry, 45,
1313-1320.
Smith, P. J., Blumenthal, J. A., Hoffman, B. M., Cooper, H., Strauman, T. A., Welsh-Bohmer, 
K., . . . Sherwood, A. (2010). Aerobic exercise and neurocognitive performance: A 
meta-analytic review of randomized controlled trials. Psychosomatic Medicine, 72,
239-252.
Smits, J. A. J., Berry, A. C., Rosenfield, D., Powers, M. B., Behar, E., & Otto, M. W. (2008). 
Reducing anxiety sensitivity with exercise. Depression and Anxiety, 25, 689-699. 
Smits, J. A. J., Berry, A. C., Tart, C. D., & Powers, M. B. (2008). The efficacy of cognitive-
behavioral interventions for reducing anxiety sensitivity: A meta-analytic review. 
Behaviour Research and Therapy, 46, 1047-1054. 
Smits, J. A. J., Meuret, A. E., Zvolensky, M. J., Rosenfield, D., & Seidel, A. (2009). The 
effects of acute exercise on CO2 challenge reactivity. Journal of Psychiatric Research, 
43, 446-454. 
Smits, J. A. J., Powers, M. B., Berry, A. C., & Otto, M. W. (2007). Translating empirically 
supported strategies into accessible interventions: The potential utility of exercise for 
the treatment of panic disorder. Cognitive and Behavioral Practice, 14, 364-374. 
Solomon, R. L. (1980). The opponent-process theory of acquired motivation: The costs of 
pleasure and the benefits of pain. American Psychologist, 35, 691-712. 
Somers, V. K., Conway, J., Johnston, J., & Sleight, P. (1991). Effects of endurance training 
on baroreflex sensitivity and blood pressure in borderline hypertension. The Lancet, 
337, 1365-1368. 
Spiegelhalder, K. A. I., Fuchs, L., Ladwig, J., Kyle, S. D., Nissen, C., Voderholzer, U., . . . 
Riemann, D. (2011). Heart rate and heart rate variability in subjectively reported 
insomnia. Journal of Sleep Research, 20, 137-145. 
Spielberger, C. D., Gorsuch, R. L., Lushene, R. E., Vagg, P. R., & Jacobs, G. A. (1983). 
Manual for the State-Trait Anxiety Inventory (Form Y). Palo Alto, CA: Consulting 
Psychologists Press. 
Stein, J. M., Papp, L. A., Klein, D. F., Cohen, S., Simon, J., Ross, D., . . . Gorman, J. M. 
(1992). Exercise tolerance in panic disorder patients. Biological Psychiatry, 32, 281-
287.
Stein, M. B., Chartier, M., & Walker, J. R. (1993). Sleep in nondepressed patients with panic 
disorder: I. Systematic assessment of subjective sleep quality and sleep disturbance. 
Sleep, 16, 724-726. 
Ströhle, A. (2009). Physical activity, exercise, depression and anxiety disorders. Journal of 
Neural Transmission, 116, 777-784. 
Ströhle, A., Feller, C., J. Strasburger, C., Heinz, A., & Dimeo, F. (2006). Anxiety modulation 
by the heart? Aerobic exercise and atrial natriuretic peptide. 
Psychoneuroendocrinology, 31, 1127-1130. 
Ströhle, A., Feller, C., Onken, M., Godemann, F., Heinz, A., & Dimeo, F. (2005). The acute 
antipanic activity of aerobic exercise. American Journal of Psychiatry, 162, 2376-
2378.
Ströhle, A., Graetz, B., Scheel, M., Wittmann, A., Feller, C., Heinz, A., & Dimeo, F. (2009). 
The acute antipanic and anxiolytic activity of aerobic exercise in patients with panic 
disorder and healthy control subjects. Journal of Psychiatric Research, 43, 1013-1017. 
83
Ströhle, A., Höfler, M., Pfister, H., Müller, A.-G., Hoyer, J., Wittchen, H.-U., & Lieb, R. 
(2007). Physical activity and prevalence and incidence of mental disorders in 
adolescents and young adults. Psychological Medicine, 37, 1657-1666. 
Ströhle, A., Kellner, M., Holsboer, F., & Wiedemann, K. (2001). Anxiolytic activity of atrial 
natriuretic peptide in patients with panic disorder. The American Journal of 
Psychiatry, 158, 1514-1516. 
Suess, P. E., Porges, S. W., & Plude, D. J. (1994). Cardiac vagal tone and sustained attention 
in school-age children. Psychophysiology, 31, 17-22. 
Tarvainen, M. P., Ranta-Aho, P. O., & Karjalainen, P. A. (2002). An advanced detrending 
method with application to HRV analysis. IEEE Transactions on Biomedical 
Engineering, 49, 172-175. 
ten Have, M., de Graaf, R., & Monshouwer, K. (2011). Physical exercise in adults and mental 
health status: Findings from the Netherlands Mental Health Survey and Incidence 
Study (NEMESIS). Journal of Psychosomatic Research, 71, 342-348. 
Ter Horst, G. J. (1999). Central autonomic control of the heart, angina, and pathogenic 
mechanisms of post-myocardial infarction depression. European Journal of 
Morphology, 37, 4, 257-266. 
Thayer, J. F. (2006). On the importance of inhibition: Central and peripheral manifestations of 
nonlinear inhibitory processes in neural systems. Dose-Response, 4, 2-21. 
Thayer, J. F., & Friedman, B. H. (2002). Stop that! Inhibition, sensitization, and their 
neurovisceral concomitants. Scandinavian Journal of Psychology, 43, 123-130. 
Thayer, J. F, Hansen, A., Saus-Rose, E., & Johnsen, B. (2009). Heart rate variability, 
prefrontal neural function, and cognitive performance: the neurovisceral integration 
perspective on self-regulation, adaptation, and health. Annals of Behavioral Medicine, 
37, 141-153. 
Thayer, J. F., & Lane, R. D. (2000). A model of neurovisceral integration in emotion 
regulation and dysregulation. Journal of Affective Disorders, 61, 201-216. 
Thayer, J. F., & Lane, R. D. (2007). The role of vagal function in the risk for cardiovascular 
disease and mortality. Biological Psychology, 74, 224-242. 
Thayer, J. F., Yamamoto, S. S., & Brosschot, J. F. (2010). The relationship of autonomic 
imbalance, heart rate variability and cardiovascular disease risk factors. International
Journal of Cardiology, 141, 122-131. 
Thayer, J. F., Åhs, F., Fredrikson, M., Sollers, J. J., & Wager, T. D. (2012). A meta-analysis 
of heart rate variability and neuroimaging studies: Implications for heart rate 
variability as a marker of stress and health. Neuroscience & Biobehavioral Reviews, 
36, 747-756. 
Todder, D., & Baune, B. T. (2010). Quality of sleep in escitalopram-treated female patients 
with panic disorder. Human Psychopharmacology: Clinical and Experimental, 25,
167-173.
van den Heuvel, O. A., Veltman, D. J., Groenewegen, H. J., Witter, M. P., Merkelbach, J., 
Cath, D. C., . . . van Dyck, R. (2005). Disorder-specific neuroanatomical correlates of 
attentional bias in obsessive-compulsive disorder, panic disorder, and 
hypochondriasis. Archives of General Psychiatry, 62, 922-933. 
Wedekind, D., Broocks, A., Weiss, N., Engel, K., Neubert, K., & Bandelow, B. (2010). A 
randomized, controlled trial of aerobic exercise in combination with paroxetine in the 
treatment of panic disorder. World Journal of Biological Psychiatry, 11, 904-913. 
Weissman, M. M., Markowitz, J. S., Ouellette, R., Greenwald, S., & Kahn, J. (1990). Panic 
disorder and cardiovascular/cerebrovascular problems: Results from a community 
survey. American Journal of Psychiatry, 147, 1504-1508. 
84
Wipfli, B. M., Rethorst, C. D., & Landers, D. M. (2008). The anxiolytic effects of exercise: a 
meta-analysis of randomized trials and dose-response analysis. Journal of Sport and 
Exercise Psychology, 30, 392-410. 
Wittchen, H.-U., & Essau, C. A. (1993). Epidemiology of panic disorder: Progress and 
unresolved issues. Journal of Psychiatric Research, 27, Supplement 1, 47-68. 
Yang, A. C., Tsai, S. J., Yang, C. H., Kuo, C. H., Chen, T. J., & Hong, C. J. (2011). Reduced 
physiologic complexity is associated with poor sleep in patients with major depression 
and primary insomnia. Journal of Affective Disorders, 31, 179-185.
Yeragani, V. K., Balon, R., Pohl, R., Ramesh, C., Glitz, D., Weinberg, P., & Merlos, B. 
(1990). Decreased R R variance in panic disorder patients. Acta Psychiatrica 
Scandinavica, 81, 554-559. 
Yeragani, V. K., Pohl, R., Berger, R., Balon, R., Ramesh, C., Glitz, D., . . . Weinberg, P. 
(1993). Decreased heart rate variability in panic disorder patients: A study of power-
spectral analysis of heart rate. Psychiatry Research, 46, 89-103. 
Årdal, G., & Hammar, Å. (2011). Is impairment in cognitive inhibition in the acute phase of 
major depression irreversible? Results from a 10-year follow-up study. Psychology
and Psychotherapy: Theory, Research and Practice, 84, 141-150. 
